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Understanding the Pathogenesis of Renal Medullary Carcinoma
Melinda Soeung, M.S.

Advisory Professors: Giulio F. Draetta, M.D., Ph.D. and Giannicola
Genovese, M.D., Ph.D.

Renal medullary carcinoma (RMC) is a lethal cancer that predominantly affects
young individuals with sickle cell trait (SCT). It is not currently understood why
RMC only affects certain individuals with SCT. We found that patients with RMC
more frequently participated in high-intensity exercise than matched controls.
Using mouse models of SCT, we demonstrated the significant increase of renal
hypoxia in the right kidney following high- but not moderate-intensity exercise. We
also demonstrated in cell culture studies that Smarcb1 is ubiquitinated for
proteasome-mediated degradation in hypoxia, and the re-expression of Smarcb1
leads to compromised proliferation in renal cells specifically in the context of
hypoxia. Overall, we proposed that the link between SCT and Smarcb1 deficiency
observed in RMC is due to renal hypoxia, which promotes the loss of Smarcb1 due
to its survival advantage in hypoxia.
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Chapter 1. Introduction
1.1 mSWI/SNF complex.
ATP-dependent chromatin remodeling complex: Adenosine triphosphate (ATP)dependent remodeling of the chromatin is one of several crucial mechanisms
involved in compacting and de-compacting Deoxyribose nucleic acid (DNA) in the
nucleus. Selective accessibility to DNA is important for controlling vital functions
for life such as DNA replication, selective gene expression, and DNA repair. In
order to respond rapidly to environmental changes caused by stress and other
factors, the eukaryotic chromatin is normally flexible and dynamic. ATP-dependent
chromatin remodeling complexes like the mSWI/SNF complex are important for
regulating the accessibility of the chromatin to transcription factors that are critical
for the maintenance of homeostasis.

Therefore, mutations in these chromatin remodelers can lead to negative
consequences in affected organisms. Genome- and exome- wide sequencing
studies have revealed that changes in chromatin regulation and epigenetic
processes play crucial roles in the development of diseases, such as cancer (1,
2). Of these mutations, analysis indicate that the most commonly mutated ATPdependent chromatin remodeling complex is the mammalian SWI/SNF
(mSWI/SNF) complex, also known as the Brg1/Bramha-associated factors (BAF)
complex(1).
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mSWI/SNF complex structure and architect: The composition of the mSWI/SNF
complex has been extensively studied. Proteomic analysis has revealed that the
mSWI/SNF is composed of up to 15 subunits that are encoded by more than 29
genes (1, 3, 4). This number of subunits and genes can lead to as many as 1400
different combinations of the complex (5). Overall, the subunits of the mSWI/SNF
complex are categorized into three modules: the ATPase module, the actin-related
protein (ARP) module, and the base or core module (4, 5).

Assembly of the complex: Using integrated biochemical techniques, Mashtalir et
al. demonstrated that the mSWI/SNF complex first forms around a heterodimer
core composed of SMARCC dimer and SMARCD (4). Contrary to a previous study,
they did not show that SMARCB1 was part of the core module (6). Interestingly,
Mashtalir et al. showed that SMARCB1 is grouped in the ATPase module after
network analysis of cross-linking mass spectrometry data, but biochemical
purification places SMARCB1 in the core module. These results suggest that
SMARCB1 may play an important role in regulating the chromatin remodeling
activity of the complex. Sen et al. in a previous study showed that SMARCB1 plays
a critical role in regulating the activity of the yeast SWI/SNF complex (7). Later, He
et al. showed that actin-related protein module couples the motions of the ATPase
and the base modules, explaining how SMARCB1 can possibly be functional in
both the base and ATPase modules (5).
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Genetic studies by Mashtalir et al. of core members of the mSWI/SNF complex
demonstrated that formation of the initial mSWI/SNF complex begins with
dimerization of SMARCC followed by the recruitment of the core subunits,
SMARCC and SMARCD to form the initial complex (4). SMARCB1 and SMARCE1
are next incorporated in the initial complex to form the base or core module of the
complex. This study showed that deletion of SMARCC resulted in almost complete
loss of complex integrity, whereas loss of other core subunits did not have as
profound effects. Of interest for our study, the deletion of SMARCB1 had the most
minor effects on the stability of the mSWI/SNF complex, suggesting that its tumor
suppressor role is derived from its activity in the ATPase module.

After the assembly of the core module, ARID1A is next incorporated into the
complex. The incorporation of ARID1A is critical for the subsequent assembly of
the ATPase module, consisting of the SMARCA4 subunit (4). The C terminus of
ARID1A is responsible for anchoring the ATPase module to the core module, and
it is the most frequently mutated mSWI/SNF subunit in human diseases. Mutations
in ARID1A probably lead to diseases like cancer by disrupting the ATPase-driven
chromatin remodeling function of the mSWI/SNF complex. SMARCA4 is the
second most frequently mutated SWI/SNF complex subunit, and it plays an
important role in interacting with the nucleosome via its C terminus and connecting
the ATPase module with the ARP module, comprising of ACTB and ACTL6A
subunits, completing the assembly of the mSWI/SNF complex (8). Cross-linking
mass spectrometry studies showed that SMARCA4 is the most extensively cross-
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linked subunit, highlighting its many interactions with other subunits throughout the
complex (8).

Overall, extensive biochemical analysis has shown that the mSWI/SNF complex
assembles in an organized stepwise manner. These studies suggest that
mutations in subunits that are involved in early assembly of the complex, such as
those in the core module are most detrimental to the integrity of the complex.
Unsurprisingly, mutations in these subunits can result in dysregulation of the
complex, leading to loss of proper chromatin remodeling function, hence diseases
like cancer. However, the mechanism of tumorigenesis for the different mSWI/SNF
subunit mutations is still largely unknown, and deeper molecular understanding is
further complicated by the varying subunit mutations in the context of tissue
specificity.

mSWI/SNF in chromatin remodeling: Despite increasing insight into the tumor
suppressor activity of the mSWI/SNF complex subunits in cancer, investigation of
the mechanism of the complex at the molecular level is still ongoing. As shown in
studies in yeast, the function of the SWI/SNF complex is to remodel the
nucleosome structure by mobilizing the nucleosome through sliding or catalyzing
the ejection or insertion of histone octamers (9). Sen et al. examined the effect of
SMARCB1 loss on the SWI/SNF complex in yeast, demonstrating that the loss of
a single subunit like SMARCB1 could lead to pleiotropic effects on the entire
complex. In this study, they proposed a model in which SWI/SNF mutations cause

4

tumorigenesis by impairing the wild-type function of the complex to mobilize the
nucleosome (7). According to this model, mutations in the SWI/SNF complex can
lead to abnormal movement of the nucleosome as a result of impaired interactions
between SWI/SNF subunits followed by altered recruitment of the subunits, which
disrupts the catalytic activity of the complex.

A recent study by He et al. further elucidated the role of the mSWI/SNF complex
in nucleosome remodeling (5). He et al. reconstituted mSWI/SNF and used cryoelectron microscopy (EM) and cross-linking mass spectrometry to show that the
mSWI/SNF complex uniquely “sandwiches” the nucleosome, providing a structural
basis to support the ejection of the nucleosome (5). They also demonstrated that
the mSWI/SNF complex was bound to nucleosome core particles in the absence
of ATP and ADP. The presence and hydrolyzation of ATP would then lead to the
ejection of the nucleosome as the complex slides along the DNA during
transcription (10). This same study also confirmed that the C-terminus helix of
SMARCB1 plays an important role in recognizing the nucleosome for remodeling
activity of the complex, and the frequent mutations found in this region can lead to
dysregulation of nucleosome ejection.

The SWI/SNF complex in yeast: The SWI/SNF complex was first studied in
Saccharomyces cerevisiae (Baker’s yeast). It has since been investigated in other
organisms, including Drosophila melanogaster and humans due to the growing
evidence of its fundamental role in human diseases. Since it has been extensively
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investigated in various organisms, there are many names for the SWI/SNF
complex and its corresponding subunits. However, for clarity, this study will refer
to the complex as the SWI/SNF complex and the HUGO names for the subunits
will be used. The principal function of the SWI/SNF complex is to orchestrate the
regulation of gene expression by coordinating the chromatin remodeling process
via ATP hydrolysis and the complex’s interaction with transcription factors.
Therefore, the SWI/SNF complex plays a major role in several cellular functions.
In effect, when the functionality of the complex is compromised, dire consequences
can arise in the form of diseases like cancer and neurological/developmental
disorders.

The genes encoding the different subunits of the complex were first revealed in
screens for mating type switching and sucrose metabolism in S. cerevisiae (11).
This genetic screen identified five new sucrose non-fermenting (Snf) alleles, Snf2,
Snf3, Snf4, Snf5, and Snf6 in addition to Snf1 as positive regulators of SUC2, a
member of the SUC gene family that encodes invertase to hydrolyze extracellular
sucrose into glucose and fructose (12). By creating mutants of each allele in S.
cerevisiae, Neigeborn and Carlson demonstrated that mutants of these five Snf
alleles, like Snf1, produced less invertase and impaired the ability of the cells to
grow on carbohydrate sources other than glucose.

Snf2 and Snf5 were later confirmed as members of the yeast SWI/SNF complex.
Both Snf2 (Brg/Brm) and Snf5 (SMARCB1) have mammalian homologs that are
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implicated in human cancer. Neigeborn and Carlson’s genetic screen
demonstrated that Snf2 and Snf5 are positive regulators that activate SUC2 and
carbohydrate metabolism differently than Snf1, Snf3, Snf4, and Snf6. This result
suggests that the SWI/SNF complex members are regulating carbohydrate
metabolism at the transcription level as opposed to directly mediating the signaling
pathway like Snf1, Snf3, and Snf4. Later, Abrams et al. demonstrated that fully
functional products of Snf2 and Snf5 are required for high level expression of
SUC2 and other glucose-repressible genes when glucose is limited, but they do
not directly mediate the regulatory signals of SUC2 (13). Later studies
demonstrated their importance as positive regulators of other glucose-repressible
genes other than SUC2 (14). In summary, the deletion of Snf5 and Snf2 impaired
the cells’ ability to grow on non-fermentable carbohydrates. However, they were
still able to grow normally on their preferred carbon source, glucose, which is a
fermentable carbohydrate.

SWI/SNF complex in cancer: Analysis of malignant rhabdoid tumors (MRTs) and
atypical/teratoid rhabdoid tumors (AT/RT) identified mutations and deletions on the
SMARCB1 locus of chromosome 22, providing the first evidence of the role of the
SWI/SNF complex in human cancer (15). Additional studies have shown that other
subunits of the SWI/SNF complex, including SMARCA4 and ARID1A are also
dysregulated in other cancers as well, supporting the emerging evidence that the
SWI/SNF complex plays a crucial role in human cancer (1).
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An analysis by Kadoch et al. of 44 primary human tumors showed that mSWI/SNF
mutations are often mutually exclusive of TP53, suggesting that the mSWI/SNF
complex plays a critical role in preventing tumorigenesis in normal cellular
physiology (1). Large-scale genomic analysis in the same study revealed that the
mSWI/SNF complex subunits were mutated in as many as 20% of human
malignancies (1). They also showed that mutations of certain subunits occurred in
specific cancer types, suggesting that cellular context is important (1). These
results lead Kadoch et al. to postulate that the tumor suppressor role of each
subunit is related to the unique assemblies of the complex and its corresponding
specific function in different tissues.

However, the mechanism of how these mutations in the mSWI/SNF complex lead
to tumorigenesis and disease development is still mostly unknown. A review by
Roberts et al. concisely summarized the many target pathways implicated in the
mSWI/SNF complex’s tumor suppressor activity. These pathways include: cell
migration, retinoblastoma (Rb), interferon-β signaling, nuclear-hormone receptor
signaling, embryonic stem cell programming, proliferation, lineage-specific
differentiation (polycomb targets), and hedgehog-Gli pathway (16).

Studies in MRTs showed that the homozygous loss of a SWI/SNF subunit could
promote tumorigenesis with almost 100% penetrance (16). However, a study by
Bultman et al. determined that mice with BAF190A heterozygosity had a tumor
penetrance of 10%, suggesting that haploinsufficiency could also cause
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tumorigenesis, although at a lesser degree (17, 18). These results suggest that
different levels of mutations could lead to different phenotypes in a dose dependent
manner.

SWI/SNF in lineage specification: Studies by several groups have demonstrated
that null or homozygous mutations of genes encoding subunits of the SWI/SNF
complex causes developmental arrest and are considered embryonic lethal (17,
19-21). For example, the loss of SMARCB1 is embryonic lethal, and we have
shown that it’s loss in somatic cells is not well tolerated either. The exact
mechanism for developmental arrest in cells with impaired SWI/SNF complexes is
still unknown, but studies suggest that this phenomenon might be related to the
SWI/SNF complex’s role in regulating cell differentiation and proliferation (22). In
fact, Panamarova et al. demonstrated that the SWI/SNF complex is acting as an
epigenetic regulator of cell lineage in the early development of the mouse embryo
(23). Panamarova et al. showed that reduced levels of BAF155 during the
developmental stage lead to increased expression of NANOG, a marker for
pluripotency, and increased levels of BAF155 lead to an increase in the expression
of gene markers for differentiation.

SMARCB1-deficient tumors: The most striking example of the detrimental effects
of the SWI/SNF complex impairment remains in the malignant rhabdoid tumor
(MRT) model in which SMARCB1 acts as a bona fide tumor suppressor. There are
data showing that in addition to MRT, the loss of SMARCB1 in subtypes of
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pancreatic cancer, ovarian cancer, bladder cancer, and kidney cancer lead to a
more aggressive disease (24-26). Studies in genetically engineered mouse
models of MRT have shown that the loss of SMARCB1 recapitulates the
aggressive tumor phenotype seen in clinic (27-29). However, the mechanism of
SMARCB1 tumor suppressor loss is still unknown.

Renal medullary carcinoma (RMC), another rare pediatric tumor that is primarily
characterized by the loss of SMARCB1, will be the focus of this study. Overall, the
loss of SMARCB1 is usually accompanied by aggressive phenotypes both
clinically and in animal models, but it’s role in disease is still poorly understood.
Understanding the role of SMARCB1 in disease can provide insight into the role of
the mSWI/SNF complex in diseases like cancer. SMARCB1 is one of the most
evolutionarily conserved members of the SWI/SNF complex, highlighting its
importance in biology. Therefore, diseases like MRT and RMC, which are driven
by the loss of SMARCB1, represent faithful models for studying the role of the
SWI/SNF complex in cancer pathogenesis.

1.2 Renal medullary carcinoma (RMC)
As mentioned, renal medullary carcinoma (RMC), is another rare pediatric tumor
of the kidney, that is also driven primarily by the loss of SMARCB1. However,
unlike MRT, RMC is characterized by another genetic disease: almost all patients
with RMC also have sickle cell trait (SCT). SCT is the most common of
hemoglobinopathies, and it is found in approximately 300 million individuals
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worldwide (30). Of these individuals, approximately 1/20,000 to 1/39,000 will
develop RMC (31). However, it is unclear why only some individuals with SCT
eventually develop RMC. All reported cases of RMC are sporadic without familial
clustering or identifiable genetic risk factors other than the presence of a SCT,
supporting the notion that RMC, unlike SCT, is not hereditary.

In 1995, Davis et al. first described RMC as the seventh sickle cell
nephropathy,(32) but the pathogenesis of the disease remains largely unknown.
Although it is relatively rare, RMC is the third most common malignancy afflicting
young adults, and the median age of diagnosis is 28 years of age (33). RMC occurs
more often in males than females with a 3:1 male:female ratio, and most patients
are of African descent (34, 35). The prognosis for RMC is very poor, and less than
5% of patients will survive beyond 36 months after initial diagnosis. Unfortunately,
RMC tumors are mostly unresponsive to best available chemotherapy, prompting
an urgent need for improved therapeutics and screening methods for the treatment
and prevention of RMC (35, 36). In addition, RMC exclusively afflicts individuals
with SCT. It is estimated that 1 out of 20,000 individuals with SCT will develop
RMC (37, 38). The strong association between SMARCB1 loss and SCT in
patients with RMC is not understood and will be investigated in this study.

RMC tumors are characterized via immunohistochemistry (IHC) detection for the
loss of SMARCB1, also known as BAF47, INI1 and hSNF5. SMARCB1 was first
identified as a tumor suppressor by Versteege et al. in malignant rhabdoid tumor
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(MRT) (15). Since then, studies using genetically engineered mouse models
(GEMM) have shown that inactivation of SMARCB1 leads to highly aggressive
tumors (24, 27, 28, 39). Similar to MRT, another rare tumor characterized by the
loss of SMARCB1, RMC tumor cells have distinct “rhabdoid” features, including
eosinophilic cytoplasm, prominent nucleoli, and an eccentrically placed cell body.
The term “rhabdoid” comes from its first description in rhabdomyosarcoma. Since
the rhabdoid feature was first seen in rhabdomyosarcoma, tumors with similar
histological features are also said to have rhabdoid-like cells. Tumor sub-types
with the rhabdoid feature are often more aggressive and accompanied by the loss
of SMARCB1, suggesting that the rhabdoid feature is caused by SMARCB1
inactivation.

Msaouel et al. utilized whole exome sequencing (WES) of 31 untreated RMC
tumors from patients to show that 40% of RMC tumors were characterized by the
loss of chromosome 22, which is the location of SMARCB1 (40). The study also
revealed that RMC has recurrent focal chromosomal amplifications and deletions.
Of these deletions, SMARCB1 locus 22q11.23 was the most common focal
deletion in RMC tumors, representing 60% of tumors. Interestingly, 46.7% of RMC
tumors had chromosome 8q gain, and RNA sequencing showed that 21.1% of
genes on 8q were upregulated in comparison to adjacent normal kidney (40). The
same study also employed a combination of fluorescence in situ hybridization
(FISH) analysis, exome DNA sequencing, and multiplex ligation-dependent probe
amplification to demonstrate that the most common alteration in RMC tumors is
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the inactivating translocation of one allele of SMARCB1 accompanied by the
deletion of the second allele (84.2% of RMC tumors) (40).

Transcriptomic analysis of RMC tumors compared to normal adjacent kidney from
patients showed that RMC has a distinct metabolic phenotype that is characterized
by a significantly enriched hypoxia signature, upregulation of the Citric Acid (TCA)
cycle genes, and conversely a decrease in genes involved in oxidative
phosphorylation (40). Overall, RMC has a distinct mutational landscape and
transcriptomic profile from other renal cell carcinomas, such as collecting duct
carcinoma despite their purported similar origin in the nephron.

1.3 Sickle cell trait and disease.
Sickling as a function of renal hypoxia: Despite the absence of red blood cell (RBC)
sickling in the peripheral blood, sickled RBCs are commonly found in the renal
medulla of individuals with SCT, suggesting that the unique hypoxic environment
of the renal medulla is conducive to RBC sickling (41, 42). Patients with SCT have
one defective allele in hemoglobin caused by a single nucleotide mutation of the
β-globin subunit, which results in the substitution of glutamic acid by valine (HbS).
Generally, patients with SCT have RBCs with normal morphology. However,
sickling of RBCs can occur under stress, such as hypoxia and low osmotic
pressure (43). Hypoxia in tissue is defined as an oxygen partial pressure ≤15 mm
Hg (≤ 2%). Most mammalian tissues have average oxygen partial pressure of 50
mm Hg (5.5% oxygen).
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Unlike other organs, the kidney is heterogeneous, meaning each region of the
kidney exhibits unique characteristics, including substantial differences in oxygen,
and the partial pressure of oxygen decreases significantly to approximately 10-20
mm Hg (1.4-2.8% oxygen) in the renal medulla. The low oxygen tension in the
inner medulla is a consequence of the countercurrent exchange caused by low
blood flow in the capillaries surrounding the loop of Henle, enabling passive
diffusion of water back into the interstitial fluid, which maintains the solute
concentration gradient of the renal medulla. Therefore, the interstitial osmolarity
increases at the collecting ducts to reabsorb water (44).

The renal medulla receives a low percentage of blood flow and has a low partial
pressure of oxygen (10 mm Hg), so there is a high ratio of oxygen extraction,
making it highly susceptible to slight changes in blood flow (45). Thus, the
physiological hypoxia of the renal medulla provides a favorable environment for
RBCs to sickle. Consequentially, patients with SCT are at risk of increased renal
ischemia, providing an extreme physiological environment that can promote
selection of cells that can survive and proliferate, but how this may directly induce
tumor development is unknown.

SCT nephropathies: Histological evaluation of patient kidneys with SCT and sickle
cell disease (SCD) revealed structural and blood vessel abnormalities, particularly
in the inner medullary and papillary regions of the kidney (46). A recent study also
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showed that patients with SCT are susceptible to declining kidney function based
on estimated glomerular filtration rate (eGFR), suggesting that SCT is not benign
as previously thought (47). When Davis et al. described the first known cases of
RMC in 1995 as the seventh sickle cell nephropathy, he postulated that the
pathogenesis of RMC might be related to tissue hypoxia caused by sickling RBCs
in the renal medulla (32). Berman et al. previously described the six sickle cell
nephropathies (gross hematuria, papillary necrosis, nephrotic syndrome, renal
infarction, the inability to concentrate urine, and pyelonephritis) all of which are
purported to be caused by sickling RBCs obstructing blood vessels (48). Despite
the strong associations observed in patients, there is still currently no evidence
supporting the hypothesis that chronic hypoxia caused by sickling RBCs in the
renal medulla is related to the pathogenesis of RMC in individuals with SCT.

SCT and exertional sickness: Unlike sickle cell disease (SCD), SCT normally
presents in clinic as a benign condition with no obvious complications (49).
However, emerging reports have observed an unsettling association between
high-intensity exercise and an increased risk of sudden cardiac arrest and
exertional rhabdomyolysis, also called “sickle cell crisis” or exertional sickness, in
individuals with SCT, presumably due to tissue hypoxia from RBC sickling (50-53).
In fact, some of the first cases of SCT complications were initially described in
military men with SCT (54). Also, it was observed that young athletes who have
SCT can suffer from complications that are sometimes fatal as a result of highintensity exercise (55, 56). Complications related to hypoxia (low oxygen
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concentration in tissues) and hypoxemia (deficient oxygen in blood) have been
reported in patients with SCD, and are usually managed with supplemental
oxygen, red cell transfusion, or hydroxyurea (57). However, the effects of highintensity exercise in the setting of SCT have not been investigated and the majority
of studies addressing RMC have been descriptive case reports that fail to address
risk factors beyond the presence of SCT (31, 41).

Studies suggest that oxidative stress could be the reason for the complications
associated with acute high-intensity exercise in individuals with SCT. For instance,
one study showed that individuals with SCT exposed to treadmill exercise had
increased erythrocyte oxidation, resulting in an increase of reactive oxygen
species (ROS) that was associated with insufficient breakdown of H2O2 (58).
Reports have shown that high-intensity aerobic exercise likely generates the most
ROS (59), explaining why individuals with SCT are more susceptible to
complications from high-intensity exercise as opposed to moderate or low-intensity
exercise. Exposure to hypoxia can also generate excessive ROS by downregulating mitochondrial complex III, hence increasing oxidative stress (60).

In particular, acute high-intensity exercise, which we model in this study, is usually
the most problematic for individuals with SCT (51). This unique susceptibility to
acute high-intensity exercise can be due to the inability of individuals with SCT to
respond to sudden increases in ROS. Normally, the body’s anti-oxidant system
would be able to regulate even extreme fluctuations in ROS via ROS-generated
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stimulation of anti-oxidant enzymes (59). However, a study showed that untrained
individuals (no history of regular exercise) with SCT did not experience the
expected increase in anti-oxidant defense enzymes seen in non-carriers of SCT
(61).

This same study also demonstrated that after habitual exercise, individuals with
SCT showed improved anti-oxidant responses similar to the control group,
suggesting that the complications of exercise seen in SCT can be overcome with
training (61). Several studies have reported that exercise training can attenuate
oxidative stress by increasing the body’s anti-oxidant system to combat excess
oxidants as summarized in a review by Radak et al (59). Therefore, the positive
effects of training with moderate or regular exercise for individuals with SCT might
be attributed to a gradual decrease in oxidative stress.

1.4 Is hypoxia the link between SCT and SMARCB1 loss in RMC?
Collectively, these observations suggest that the consequential hypoxia/anoxia
resulting from sickling RBCs in the renal medulla may be the link between SCT
and the loss of the tumor suppressor SMARCB1 seen in RMC patients. The
hypoxia/anoxia caused by sickling RBCs may be creating a pressure that selects
for cells with the genetic fitness to adapt and survive in the harsh conditions caused
by renal ischemia. However, studies in cardiac disease have shown that
physiological adaptations to stress can become maladaptive if the stressor is
chronic (62). In the context of RMC, this adaptive mechanism may be initially the
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loss of the tumor suppressor SMARCB1. Evaluation of clinical samples of RMC
show the loss of SMARCB1 protein based on immunohistochemical analysis.
Aside from its role as a tumor suppressor, SMARCB1 is a core member of the
larger mSWI/SNF complex, a chromatin remodeler that has been implicated to be
mutated in more than 20% of human cancers (63).

In general, the SWI/SNF complex has many functions that are critical for the
maintenance of cellular homeostasis (16). Independent of the SWI/SNF complex,
studies have demonstrated the critical role of SMARCB1 as a tumor suppressor,
and its loss alone is enough to drive MRT and RMC (15, 28, 40, 64). Studies have
also shown the importance of SMARCB1 in normal cellular physiology,
demonstrating that losing SMARCB1 is embryonically lethal (39). However, the
role of SMARCB1 in cellular hypoxia response is presently unknown, and we will
investigate the molecular underpinnings of SMARCB1 and hypoxia in this study.
Therefore, we hypothesize that the loss of SMARCB1 confers a selective
advantage for cells to survive in extreme conditions such as hypoxia and nutrient
deprivation that can lead to tumorigenesis (Schematic 1).
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Schematic 1. Schematic of main hypothesis.
1.5 Significance/Need
Alterations in the SWI/SNF complex have been increasingly implicated in different
cancers. The complex’s role in regulating crucial developmental pathways is
further supported by clinical data showing that inactivation or aberration of a core
subunit, SMARCB1, results in the emergence of highly aggressive tumors,
including MRT and RMC. SMARCB1-deficient tumors are classified as orphan
diseases and are managed with a combination of high doses of chemotherapy,
radiation therapy, and surgery (65). Unfortunately, these approaches are
marginally effective, leading to a poor survival rate for patients who have these
neoplasms.

In particular, there is a critical need for the development of new screening methods
to diagnose and prevent RMC that is guided by understanding of what drives its
unique epidemiology. Despite best available treatment, patients with RMC

19

continue to have poor prognoses with a median survival of only 13 months from
the time of diagnosis (41, 66, 67). Patients are usually diagnosed with RMC
between the ages of 11-39 years of age, and it is characterized by early and
widespread metastases with a median survival of four months following initial
diagnosis. Only 5% of RMC cases are localized, and about 71.3% of RMC patients
have one site of metastatic disease at the time of diagnosis (68). Inevitably, greater
than 90% of patients with RMC will be diagnosed with advanced stage disease
(stage III or IV) (67). Unfortunately, it has been challenging to study SMARCB1deficient tumors like RMC in the laboratory due to the embryonic lethality of
SMARCB1 loss. This study will utilize novel approaches learned from the
embryonic mosaic model for malignant rhabdoid tumor of the liver (MRTL) we
developed in a previous study to establish renal tumor cell line models with
SMARCB1-deficiency that we will use for further in vitro studies (28).

Understanding the pathogenesis of RMC can also help identify risk factors for
developing RMC in individuals with SCT, who ordinarily present as healthy in the
clinic. A deep molecular understanding of how cells survive and thrive under
conditions of physiological stress, and how this leads to cancer or other diseases,
is anticipated to identify novel therapeutic opportunities to intervene in cancer or
other diseases with SMARCB1 loss or in which hypoxia-driven metabolic programs
underlie the pathology.

20

The overall goal of this research is to elucidate the role of Smarcb1 in the cellular
response to hypoxia. We hypothesize that the loss of SMARCB1 confers a
selective advantage for cells to survive in an extreme microenvironment (i.e.
chronic and extreme hypoxia) that leads to the clonal expansion of surviving cells.
We will also seek to understand the mechanism of cell survival in hypoxic
conditions using genetic and biochemical approaches. This research is significant
because it will enable functional studies of a potential link(s) between tumor
suppressor loss and/or epigenetic reprogramming and hypoxia. This research is
innovative because it will produce data for RMC, an orphan disease for which there
is a paucity of data regarding the molecular underpinnings of disease, as well as
limited resources for studying the disease, and it will help identify new drug targets.

Chapter 2. Materials and Methods
2.1 Animal model studies.
Mouse strains:
The Townes model of SCT (hα/hα::βA/βS) was generated by Dr. Tim Townes’s
laboratory and obtained through Jackson Laboratory (Stock No. 013071) (69). The
Cdh16-Cre strain was generated by Peter Igarashi’s laboratory and obtained
through

Jackson

Laboratory

(Stock

No.

012237).

The

Gt(ROSA)26Sortm2(HIF1A/luc)Kael strain was generated by Dr. William G. Kaelin’s
laboratory and obtained through Jackson Laboratory (Stock No. 006206) (70). The
Rosa26LSL-TdT was generated by Dr. Hongkui Zeng’s laboratory and obtained
through the Jackson Laboratory (Stock No: 007908) (71). Strains were kept in a
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mixed C57BL/6J and 129Sv/Jae background. The Rosa26-Cas9 knockin mouse
was generated by Dr. Feng Zhang and purchased from Jackson Laboratory (Stock
No. 026179) (72). The strain was kept in a C57BL/6J pure background. All animal
studies and procedures were approved by the UTMDACC Institutional Animal Care
and Use Committee.

Genotyping conditions:
Townes model (hα/hα::βA/βS): The common (mouse beta KI) forward primer is 5’TTGAGCAATGTG GACAGAGAAGG; the Beta A reverse primer is 5’GTTTAGCCAGGGACCGTTTCAG;

the

Beta

S

reverse

primer

is

5’-

AATTCTGGCTTATCGGAGGCAAG; the reverse primer for mouse beta wild type
is 5’- ATGTCAGAAGCAAATGTGAGGAGCA. The separated PCR conditions are
as follows: 94°C for 2 minutes, continue PCR for 10 cycles at 94°C for 20 seconds,
65°C with 0.5°C decrease per cycle for 15 seconds, 68°C for 10 seconds, continue
PCR for 28 cycles at 94°C for 15 seconds, 60°C for 15 seconds, 72°C for 10
seconds.

Cdh16-Cre:

The

forward

primer

for

the

transgene

is

5’-

GCAGATCTGGCTCTCCAAAG; the forward primer for the internal positive control
is 5’- CAAATGTTGCTTGTCTGGTG; the reverse primer for the internal positive
control is 5’- GTCAGTCGAGTGCACAGTTT; the reverse primer for the transgene
is 5’- AGGCAAATTTTGGTGTACGG. The touchdown PCR cycling conditions are
as follows: 94°C for 2 minutes, continue PCR for 10 cycles at 94°C for 20 seconds,
65°C with 0.5°C decrease per cycle for 15 seconds, 68°C for 10 seconds, continue
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PCR for 28 cycles at 94°C for 15 seconds, 60°C for 15 seconds, 72°C for 10
seconds.

Gt(ROSA)26Sortm2(HIF1A/luc)Kael:

The

CGGTATCGTAGAGTCGAGGCC;

mutant

the

mutant

GGTAGTGGTGGCATTAGCAGTAG; the
AAGGGAGCTGCAGTGGAGTA;

the

forward
reverse

wild-type

wild-type

primer
primer

forward
reverse

is

5’-

is

5’-

primer is 5’primer

is

5’-

CCGAAAATCTGTGGGAAGTC. The separated PCR conditions are as follows:
94°C for 2 minutes, continue PCR for 10 cycles at 94°C for 20 seconds, 65°C with
0.5°C decrease per cycle for 15 seconds, 68°C for 10 seconds, continue PCR for
28 cycles at 94°C for 15 seconds, 60°C for 15 seconds, 72°C for 10 seconds.

Rosa26LSL-TdT allele: The

forward

primer for wild-type

Tomato

is 5'-

AAGGGAGCTGCAGTGGAGTA; the reverse primer for wild-type Tomato is 5’CCGAAAAATCTGTGGGAAGTC; the forward primer for Tomato mutant is 5'CTGTTCCTGTACGGCATGG; the reverse primer for Tomato mutant is
5’- GGCATTAAAGCAGCGTATC. The touchdown PCR cycling conditions are as
follows: 10 cycles at 94°C for 20 seconds, 65°C and 0.5°C per cycle decrease for
15 seconds, 68°C for 10 seconds. Continue the PCR reaction for 28 cycles at 94°C
for 15 seconds, 60°C for 15 seconds, 72°C for 10 seconds.

Rosa26-Cas9 knockin on C57BL/6J allele: The forward primer for wild-type is 5’CTGGCTTCTGAGGACCG;

the

reverse
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primer

for

wild-type

is

5’-

AGCCTGCCCAGAAGACTCC.
GCTAACCATGTTCATGCCTTC;

The
the

forward
reverse

primer

for

mutant

is

5’-

primer

for

mutant

is

5’-

CTCCGTCGTGGTCCTTATAGT. The touchdown PCR cycling conditions are as
follows: 10 cycles at 94°C for 20 seconds, 65°C and 0.5°C per cycle decrease for
15 seconds, 68°C for 10 seconds. Continue the PCR reaction for 28 cycles at 94°C
for 15 seconds, 60°C for 15 seconds, 72°C for 10 seconds.

Ex vivo multiphoton microscopy analysis of mouse models:
To measure renal ischemia, four adult wild-type mice and five SCT mice were
injected with fluorescein isothiocyanate (FITC)–dextran 500,000 KDa (Sigma
Aldrich) and euthanized after five minutes followed by kidney removal for
multiphoton microscopy analysis of perfusion of the renal medullary vasculature
(73, 74). The large molecular weight dextran was used to prevent filtration outside
the renal tubules. Kidneys were removed and monitored by multiphoton
microscopy (Trimscope II, LaVision BioTech) using a long working distance 25x
NA 1.05 oil/water objective (Olympus) (73, 74). The microscope was equipped with
three titanium (Ti):sapphire lasers (Chameleon-XR, Coherent) and two optical
parametric oscillators (APE/Coherent), resulting in a tunable excitation range from
800 to 1300 nm (73). Detection of blood vessels and kidney cells was achieved by
spectral separation of FITC (525/50, 920 nm) and RFP (595/40, 1090 nm), and 3D
stacks were obtained for up to 300 µm depth at 10 µm step size. Images from
individual 3D stacks were reconstructed and analyzed using FIJI (74). Vessel
diameter and length were measured manually. The diameter was measured in 10
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vessels/image, in three different location within each vessel. The length was
measured in 10 vessels/image.

IVIS imaging:
In vivo imaging system (IVIS) was used to detect luciferase activity in mice. Mice
with pigmented fur were shaved prior to imaging to prevent background caused by
melanin in fur. Wild-type mice and mice with SCT were injected with 100 µL of 150
mg/kg of d-luciferin bioluminescence substrate (Perkin Elmer) via intraperitoneal
injection (IP) and imaged five minutes after the injection. Living Image 4.3 software
was used for analyzing images after image acquisition.

Pimonidazole hydrochloride (Hypoxyprobe):
Renal hypoxia was measured using pimonidazole hydrochloride (Hypoxyprobe).
Adult wild-type mice (n=52) and mice with SCT (n=31) were injected with 100 µL
of 60 mg/kg of pimonidazole hydrochloride three hours prior to sacrifice. Mice were
then anesthetized using isoflurane (Henry Schein Animal Health), and kidneys
were removed and immediately fixed with 10% formalin for 24 hours at room
temperature for further IHC studies. The amount of time between removal of the
kidneys from mice and fixing in formalin was minimized in order to accurately
measure tissue hypoxia.
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Immunohistochemistry (IHC):
IHC was performed on FFPE whole kidney sagittal sections. The sagittal kidney
sections were fixed in 10% formalin, embedded, and 5 µm sections were cut using
a microtome (Leica RM2235). The sections were then baked on slides, deparaffinized, and treated with citrate buffer (Electron Microscopy Sciences) for
antigen retrieval according to the manufacturer’s instructions. Endogenous
peroxidases were then inactivated using 3% hydrogen peroxide (Sigma-Aldrich)
for 10 minutes followed by washing with phosphate buffer saline. Non-specific
signals were then blocked for 20 minutes using Rodent Block M (Biocare Medical).
Samples were then stained with 1:200 primary Hypoxyprobe antibody conjugated
with horseradish peroxidase (HRP, rabbit, Hypoxyprobe) for 12 hours overnight in
4°C. After an overnight incubation, slides were washed three times using
phosphate buffer saline before staining with Rabbit-on-Rodent HRP polymer
(Biocare Medical) for one hour at room temperature. NovaRED peroxidase
substrate (Vector Lab) was used for HRP detection (10 minutes of exposure).
Hematoxylin was used for counterstaining and eosin was used to detect the
cytoplasm of cells in tissue slides. A Nikon EclipseTi microscope and Nikon DSFi1 digital camera were used to capture 20x images.

Equal areas of each 20x image were then quantified using ImageJ/FIJI. Using FIJI,
the IHC images were deconvoluted into three channels. The optical densities of
the DAB channel images were then quantified and graphed into GraphPad for
further statistical analysis.
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For dual color IHC staining, Mach 2 Double Stain 2 (Biocare Medical) was used.
EIF2-alpha was stained with anti-mouse polymer horse radish peroxidase (HRP)
and SMARCB1 was stained with anti-rabbit polymer alkaline phosphatase (AP).
For each patient sample (n=10) 10 areas of 20x images were taken and quantified
for SMARCB1 protein loss. The average of each patient sample was calculated
and graphed as a percentage over total nuclei.

Mouse forced exercise:
Adult untrained mice, n=11 wild-type mice and n=10 SCT mice, were placed on a
six-lane mechanical treadmill (Columbus Instruments) that was quickly brought up
12 to 15 meters/minute to model acute exercise. Each session lasted 10 minutes.
Mice were encouraged to continue running by using a soft-bristled tube cleaning
brush to gently push them from behind if they began to lag. For IVIS imaging
studies, mice were imaged prior to exercise, after exercise, and one hour after
exercise. Moderate-intensity exercise was defined as 12 meters/minute, which
correlates with 65% to 75% VO2 max in humans, i.e. a brisk walk.(75) Highintensity exercise was defined as 15 meters/minute, which correlates with
approximately 80% VO2 max in humans.(75) Luciferase activity was normalized to
the left wild-type kidney per mouse for further statistical analysis.

27

Single-guide RNA design and validation
Single-guide RNAs (sgRNAs) were designed with “GenScript CRISPR sgRNA
Design Tool” (https://www.genscript.com/gRNA-design-tool.html?a=post). First,
5`-phosphorilated oligos were annealed and diluted 1:20. Then 1 uL of each
annealed and diluted sgRNA was cloned in digested lentiCRISPR V2 (addgene
#52961)

according

to

Dr.

Feng

Zhang’s

protocol

(https://media.addgene.org/cms/files/Zhang_lab_LentiCRISPR_library_protocol.p
df). NEB® Stable Competent E. coli (C3040I) colonies resistant to ampicillin
antibiotic selection were amplified, and presence of sgRNA was confirmed by
Sanger sequencing. Positive clones were transfected individually in 293 cells along
with vectors for lentiviral packaging production, PAX2 (addgene #12260) and
PMD2G (addgene #12259). MCT cells were infected by the lentivirus carrying a
specific sgRNA and selected for puromycin resistance. Cut efficiency of sgRNA
was tested by T7 Endonuclease I (NEB #M0302L) assay on the DNA of infected
cells,

according

to

the

protocol

(https://www.neb.com/protocols/2014/08/11/determining-genome-targetingefficiency-using-t7-endonuclease-i). Single-guide RNA-mediated deletion was
tested by PCR amplification.

Surgical procedures
Orthotopic injection in kidney. First, 10^10 adeno-associated viral particles were
resuspended in PBS (Thermo Fisher Scientific) and Matrigel matrix (Corning) 1:1
solution. Six- to nine-week-old mice were shaved and anesthetized using
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isoflurane (Henry Schein Animal Health). Analgesia was achieved with
buprenorphine SR (0.1 mg/Kg BID) (Par Parmaceutical) via subcutaneous
injection, and shaved skin was disinfected with 70% ethanol and betadine
(Dynarex). A 1-cm incision was performed on the left flank through the
skin/subcutaneous and muscular/peritoneal layers. Left kidney was exposed and
20 uL of viral resuspension was introduced by Hamilton syringe into the organ by
a subcapsular injection. Hemostasis was controlled with a bipolar cautery (Bioseb)
if needed. The kidney was carefully repositioned into the abdominal cavity, and
muscular/peritoneal planes were closed individually by absorbable sutures. The
skin/subcutaneous planes were closed using metal clips. Mice were monitored
daily for the first three days, and twice/week thereafter for signs of tumor growth
by manual palpation.

Euthanasia, necropsy, and tissues collection
Mice were euthanized by exposure to CO2 followed by cervical dislocation. A
necropsy form was filled in with mouse information, tumor size and weight,
infiltrated organ annotations, and metastasis number and location.

Tumor cell isolation and culture
Ex vivo cultures from primary tumor explants were generated by mechanical
dissociation and incubation for 1 hour at 37°C with a solution of collagenase
IV/dispase (4 mg/mL) (Invitrogen), resuspended in DMEM (Lonza) and filtered.
Cells derived from tumor dissociation and digestion were plated on gelatin 0.1%
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(Millipore Sigma) coated plates and cultured in DMEM (Lonza) supplemented with
20% FBS (Lonza) and 1% penicillin–streptomycin and kept in culture for less than
5 passages.

In vivo treatment study in NOD scid gamma (NSG) mice
NSG female mice were subcutaneously injected with 1x106 RMC219-tet-inducible
and RMC219-tet-empty cells resuspended in 200ul of 1:1 Matrigel (BD
Biosciences, 356231) and media mixture. Cells were cultured off of DOX prior to
transplantation. Once the tumor reached approximately 100mm3 mice were placed
on doxycycline water for three days before starting treatment with Axitinib. Mice
were kept on doxycycline water throughout the experiment. Axitinib was
administered via oral gavage at 30mg/kg every day for 14 days (n=10). Axitinib
was dissolved in 0.5% CMC solution. Control mice received 0.5% CMC vehicle
alone (n=10). Tumor volume was measured every three days by caliper, and the
body weight was also monitored. Tumor volume (mm3) was calculated using the
following formula: V (mm3) = L (mm) × W (mm) 2 /2, where W is tumor width and
L is tumor length. Mice were sacrificed after 14 days of treatment according to
approved guidelines of the Institutions Animal Ethics Committee. Tumors were
harvested, weighed, and fixed in formalin for histological analysis.
2.2 Patient studies.
Patient Population:
Clinical and histologic data from patients with pathologically confirmed RMC
treated at a single institution were collected from January 2011 to February 2020.
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All histology was reviewed by a genitourinary pathology expert and the RMC
samples

were

confirmed

to

be

SMARCB1

negative

staining

by

immunohistochemistry (IHC). Clinical and demographic variables were collected.
All patients were also assessed retrospectively for regular physical activity or
military service according to guidelines by the American Heart Association (76).
This included assessment of the 4 dimensions (mode, frequency, duration and
intensity) and domains (occupational, domestic, transportation and leisure time) of
physical activity (76).

Reported involvement in organized athletic activities,

exercise ≥ 3 times per week, participation in endurance racing, or prior military
service were recorded if present. A binary “activity index” was created whereby
patients with involvement in any of the above listed exercise activities were coded
as “1” (“yes”) and those without involvement in any exercise activity were coded
as “0” (“no”).

We generated a matched control group to determine whether reported exercise
(as measured by the same activity index) and anthropometric measurements were
associated with RMC using a case-control approach. Because it is well established
that advanced malignancies, including advanced RMC, can lead to sarcopenia and
cachexia,(77) the matched control patients (all evaluated in the same department
and time period as the patients with RMC) also had similarly staged genitourinary
malignancies and were matched with each patient with RMC in a 2:1 ratio
whenever possible based on age and biologic sex. Malignancies included
testicular cancer, renal cell carcinoma (RCC), prostate cancer, and bladder cancer.
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We generated a matched control group to determine whether reported exercise
(as measured by the same activity index) and anthropometric measurements were
associated with RMC using a case-control approach. Because it is well established
that advanced malignancies, including advanced RMC, can lead to sarcopenia and
cachexia,(77) the matched control patients (all evaluated in the same department
and time period as the patients with RMC) also had similarly staged genitourinary
malignancies and were matched with each patient with RMC in a 2:1 ratio
whenever possible based on age and biologic sex. Malignancies included
testicular cancer, renal cell carcinoma (RCC), prostate cancer, and bladder cancer.

Physical activity evaluation:
To determine the presence of high-intensity physical activity, both RMC and control
patient medical records were retrospectively evaluated. We applied the same
strategy to all patients based on the American Heart Association’s “Guide to
Physical Activity Assessment” (76). We first evaluated the 4 dimensions of physical
activity including the mode or type of activity (e.g. walking, cycling, weightlifting),
frequency of performing the activity, duration of performing the activity and the
intensity of performing the activity. In addition, we evaluated the domains of
physical activity including occupational, domestic, transportation, and leisure time.
Based on reported occupations among our RMC and control patients, we only
considered occupations with significant manual labor or high-intensity exercise
component as indicative of significant physical activity. These occupations
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included construction, professional/full time athlete, and personal exercise
trainers. Domestic physical activity such as housework, yard work or childcare
were not considered indicative of significant high-intensity physical activity. Patient
reported exercise including participation in sporting events, bicycling, weightlifting,
running, and martial arts ≥3 times per week were considered significant physical
activity. The number of hours patients participated in each physical activity per
week were collected; however, this was infrequently reported among patients both
in the RMC and control cohorts. These criteria were applied equally to both groups.
A binary physical activity index was then created to compare the RMC and
matched controls. If a patient reported at least one domain of physical activity, they
were tabulated as 1 or “yes” and if no physical activity domains were reported then
they were tabulated as 0 or “no”. This binary system would reduce bias when
comparing the proportion of physical activity between the two cohorts.

Anthropometric analysis:
We objectively measured the cross-sectional area of skeletal muscle (SM) and
subcutaneous adipose (SA) compartments using computed tomography (CT)
imaging studies. Images were obtained and analyzed at the initial diagnosis of
cancer prior to initiation of systemic therapy to avoid the changes induced by
systemic therapy on either SM or SA. We then compared the two compartments
between the RMC and control patients. The SM and SA areas were measured
using axial images at the midpoint of the L3 vertebral body as previously described
(78). Cross-sectional areas were standardized to the square of height in meters
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for each patient. Analysis was performed using SliceOMatic v5.0 (TomoVision,
Magog, Canada).

Epidemiologic comparison:
We hypothesized that active-duty military service may increase the rate of highintensity exercise and be more prevalent in our RMC cohort. We accordingly
compared the proportion of military service among our RMC cohort to that of a
similarly aged (age 20-40 years old) U.S. population of black individuals with SCT.
To estimate this population, we used U.S. census bureau data from 2018 which
report that 41,617,764 individuals identify as black (about 12.7% of the U.S.
population) (79). Of this population, about 35% (14,566,217) are between 20 and
40 years old, which is the age most likely to be affected by RMC (79). Department
of defense data from 2018 report that there are 222,705 black individuals serving
on active duty age 20 to 40 years old (80). Sickle cell trait affects about 8% of
black individuals(31); thus, there are about 1,165,297 black individuals age 20 to
40 years with SCT in the U.S., of which a total of 17,816 (1.5%) are on active duty
in the U.S. military.

Prospective exercise evaluation:
We prospectively gathered detailed information on the exercise activity of 7
additional patients with RMC seen as new patients at our institution from March
2020 until January 2021. These patients were asked to grade their exercise
intensity as high, medium, or low. High-intensity exercise was defined as achieving
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near maximal effort by performing at ≥80% maximal heart rate during each
exercise session (81). Moderate-intensity exercise was defined as exercise
performed in a continuous manner at lower intensities than high-intensity exercise
during each exercise session (81). Patients who did not participate in regular
exercise activities were reported as “none”. Patients also reported how much time
per week was spent exercising. Lastly, we recorded the type of exercise activities
patients participated in and how long they had been involved in these activities
prior to the diagnosis of RMC.

2.3 Statistical analysis.
Data was graphed using Prism GraphPad. Two-way ANOVA and Tukey multiple
comparison tests were used to compare the changes in Hif1α–luciferase activity
for exercise experiments. Student’s t-test was used to calculate P-value for all
other analysis.

2.4 In vitro studies.
Cell lines:
IMCD-3 cell line: IMCD-3 (inner medulla collecting duct) mouse cell lines were
purchased from ATCC. IMCD-3 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM/F12) (ThermoFiscer Scientific) supplemented with 1% pencillinstreptomycin (Gibco) and 10% fetal bovine serum (FBS) (Gibco). Cell lines were
cultured in at 37οC with 5% CO2. All cells were tested for Mycoplasma
contamination using MycoAlert.
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RMC219-tet-inducible SMARCB1 cell line: The tetracycline-inducible pIND20fSNF5-HA vector (82) was kindly donated by Dr. Bernard E. Weissman. The
pInducer20 empty backbone (83) was a gift from Stephen Elledge (Addgene
plasmid # 44012 ; http://n2t.net/addgene:44012 ; RRID:Addgene_44012).
Lentivirus was generated in HEK-293FT cells and used to generate stable tetinducible cell lines as previously described (84). RMC219 (also called JHRCC219),
a human tumor cell line that was established in a previous study(85), was infected
with tetracycline-inducible pIND20-fSNF5-HA vector. Cells were treated with 2 μg
of doxycycline (DOX) for three days to re-constitute SMARCB1 (SNF5).

Immunoblotting/Western Blotting:
Cells were lysed with RIPA buffer containing protease inhibitor. Protein lysates
were resolved on 5–15% gradient polyacrylamide SDS gels and transferred onto
PVDF membranes according to manufacturer’s instructions. Membranes were
incubated with indicated primary antibodies, washed in TBST buffer and probed
with HRP-conjugated secondary antibodies. The detection of bands was carried
out upon chemiluminescence reaction followed by film exposure.

Immunoprecipitation (IP):
For IP experiments, cell lysates were prepared using RIPA buffer containing
protease inhibitor. 5 μg of anti-SMARCB1 (Bethyl laboratories, rabbit) was
incubated with 50 μL of Protein A Magnetic Beads (New England BioLabs,

36

catalog# S1425S) overnight at 4C. Afterwards, beads were washed three times
with phosphate buffer saline (PBS), and incubated with 1 mg of protein lysate
overnight at 4οC. After overnight incubation, beads were washed with PBS eight
times in 4οC. To elute beads, beads were incubated with 0.1 M glycine at room
temperature for 10 minutes. Elution was then removed from beads (careful not to
include beads) and used for further immunoblotting analysis. To avoid detection of
heavy chain, anti-SMARCB1

(BD

laboratories, mouse) was used

for

immunoblotting analysis.

Table 1. Chemical reagents and antibodies.
Protein name

Vendor

Catalog

Species

Concentration

number
SMARCB1

Sigma Aldrich

HPA018248

Rabbit

1:200

SMARCB1

BD

612110

Mouse

1:500

Laboratories
VINCULIN

Cell Signaling

4650S

Mouse

1:2000

β-ACTIN

Cell Signaling

4967S

Mouse

1:2000

HIF-1α (D2U3T) Cell Signaling

14179

Rabbit

1:1000

SMARCB1

A301-087A

Rabbit

5 ug

Cell Signaling

3936

Mouse

1:1000

Cell Signaling

9722

Mouse

1:200

Bethyl
Laboratories

UBIQUITIN
(P4D1)
eIF2-alpha
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Axitinib

Selleckchem

AG 013736

MG-132

Selleckchem

S2619

Cycloheximide

Selleckchem

NSC-185

Dimethyl

Sigma Aldrich

67-68-5

sulfoxide
(DMSO)

Site-directed mutagenesis (SDM).
The amino acid sequence for SMARCB1 (human) was retrieved from NCBI
(source:
https://www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi?REQUEST=GV&D
ATA=574903&BUILDS=CURRENTBUILDS ). BIOGRID was used to identify
lysine residues on SMARCB1 that were shown to be ubiquitinated in previous
studies. Listed lysine (K) and arginine (R) residues (See Table 2) were converted
to arginine (R) and histidine (H), respectively. For deletions, the residue was
replaced by a STOP codon. Hotspot mutations R377H, K364, and K363 deletion
were also included in this study. SMARCB1 mutant sequences and wild-type
sequence were then cloned into pDONR 221 Gateway donor vector (Invitrogen).
Gateway cloning method was used to ligate donor vector into destination vector
pHAGE-IRES-PURO. SMARCB1 mutants were then reconstituted into SMARCB1
deficient cell lines, and positive clones were selected using puromycin.
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Table 2. List of residues that were mutated using SDM (modified from BIOGRID).
Location

PTM

Residue

Source(s)

13

Ubiquitination

K

Akimov V (86)
Rose CM (87)
Stukalov A (88)
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Ubiquitination

K

62

Ubiquitination

K

106

Ubiquitination

K

Rose CM (87)

Akimov V (86)
Emanuele MJ (89)
Rose CM (87)
Sarraf SA (90)

108

Ubiquitination

K

Akimov V (86)
Sarraf SA (90)

124

Ubiquitination

K

Akimov V (86)

199

Ubiquitination

K

Akimov V (86)
Stes E (91)

286

Ubiquitination

K

Povlsen LK (92)

292

Ubiquitination

K

Akimov V (86)
Li W (93)
Povlsen LK (92)
Wagner SA (94)

296

Ubiquitination

K

Povlsen LK (92)

363

Ubiquitination

K

Udeshi ND (95)
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Virus preparation:
Infectious viral particles were produced using helper plasmids psPAX2 and
pMD2G obtained through Addgene. 293T cells were cultured in DMEM containing
10% FBS (Gibco), 100 μg/ml Penicillin/Streptomycin (Gibco) and transfected using
the Polyethylenimine (PEI) method. Virus-containing supernatant was collected 72
hours after transfection, spun at 3000 rpm for 10 minutes and decanted (96). Hightiter preps were obtained by a single round of ultracentrifugation at 24,000 RPM
for 2.5 hours.
Clonogenic assay:
After allowing cells to grow at certain conditions, media was removed, cells were
washed once with phosphate buffer saline (PBS), and 0.5% crystal violet (CV)
solution was added to cells. Cells were gently incubated on a shaker at room
temperature for one hour. After one hour of incubation, CV solution was removed,
and residual CV was washed completely away with water. 10% acetic acid was
used to dissolve CV, followed by further quantification by measuring the
absorbance of CV at 550 nm using a spectrophotometer.

Fluorescence in situ hybridization (FISH) analysis:
Paraffin sections of patient samples were used for FISH analysis. SMARCB1A-20GROR break apart probe (Empire Genomics) containing an orange telomeric label
and a green centromeric label was used to label SMARCB1 gene. Partial loss of
SMARCB1 was defined as loss of either green or orange probes. Analysis of
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SMARCB1 loss was performed on n=10 different patient samples. 10 different
images were taken per patient sample and the average per sample. The average
number of partial deletions of SMARCB1 per image (10 cells) was averaged per
patient. The average percentage of partial SMARCB1 loss over total cells per
patient samples was graphed in GraphPad.

2.5 RNA sequencing.
After controlling for the quality of the initial samples, rRNA depletion was performed
for the total RNA for each sample, followed by random-primed and stranded cDNA
preparation and quality control. Total RNA was converted into a library of template
molecules for sequencing on Illumina HiSeq2000, with a paired-end read length of
100 to 125 nt. The quality of the FASTQ reads was evaluated using the FastQC
software (97). The raw reads in FASTQ format were aligned to the reference
human genome, hg19, using the MOSAIK alignment software (98). Gap alignment
was performed using the Smith-Waterman algorithm in MOSAIK. Gene-level
annotation was carried out using the GENCODE annotation, which was
downloaded from the GENCODE project (99). The overlaps between aligned reads
and annotated genes were counted using HTSeq software (100). Gene counts
were normalized using the scaling factor method. If the number of overlapped
reads of any given gene was less than one per million total mapped reads for all
samples, this gene was excluded from further analysis. Hierarchical clustering
analyses were performed using the Pearson correlation coefficient as the distance
metric and the ward’s linkage rule. Principle component analyses (PCA) were also
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performed to explore the multi-gene structure. A negative binomial model was fit
to the read counts of each gene. Then a Wald test was used to test the null
hypothesis of no difference in gene expression between two conditions, e.g., tumor
vs normal samples. The Benjamini & Hochberg (BH) method was used to control
false discovery rate (FDR). These methods were implemented in the DESeq2
(101) run on R version 3.2.3. Pathway diagram templates were taken from Chen
et al. (102).

2.6 Gene-set enrichment analysis (GSEA).
We performed GSEA (103) of RNA-seq data using the R-GSEA script run in R
version 3.2.3 using the following gene sets collected at the Molecular Signatures
Database

(MSigDB)

(http://software.broadinstitute.org/gsea/msigdb/collections.jsp): (i) Fifty hallmark
gene sets, which summarize and represent specific well-defined biological states
or processes and display coherent expression. These gene sets were generated
by a computational methodology based on identifying overlaps between gene sets
in other MSigDB collections and retaining genes that display coordinate expression
(104); (ii) Canonical pathway gene sets curated from online databases including
BIOCARTA, KEGG, and REACTOME; (iii) Gene Ontology (GO) gene sets.

42

Chapter 3. Results
Part 1: Association of high-intensity exercise with renal medullary carcinoma in
individuals with sickle cell trait.
3.1 SCT mice have significantly higher renal hypoxia than wild-type mice.
We hypothesized that the connection between SCT and the loss of SMARCB1
seen in RMC tumors is hypoxia caused by ischemia. Therefore, to test whether
renal ischemia exists in the presence of SCT, we generated a genetically
engineered mouse model (GEMM) of SCT that leverages fluorescence for imaging
purposes. The CDH16Cre strain was crossed with the conditional Rosa26LSL-TdT
strain and the hα/hα::βS/βS strain to generate a GEMM of SCT (hα/hα::βA/βS) that
allows for tissue specific activation of TdTomato (TdT) fluorescence reporter in the
kidney epithelium (Figure 1).

Figure 1. Schematic of genetically engineered mouse model (GEMM) of SCT. The
CDH16Cre strain was crossed with the conditional Rosa26LSL-TdT strain and the
hα/hα::βS/βS strain to generate a GEMM of SCT (hα/hα::βA/βS) that allows for tissue
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specific activation of TdTomato (TdT) fluorescence reporter in the kidney
epithelium.

Pathological evaluation confirmed RBC sickling in mice with SCT, particularly in
the renal medullary (Figure 2). However, evaluation of peripheral blood showed
no RBC sickling in mice with sickle cell trait, supporting the notion that the hypoxic
environment of the renal medulla is selectively conducive to RBC sickling in
individuals with sickle cell trait (Figure 3).
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Figure 2. Hematoxylin and eosin staining of kidney tissue from wild-type mice (A)
and mice with SCT (B). Sickle morphology is apparent in mice with SCT. Sickled
RBCs have spindle-like morphology and are indicated with yellow arrows.
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Figure 3. Blood smear from mice with wild-type and sickle cell trait mice. Blood
was drawn from the tail vein of mice, fixed with methanol, and stained with giemsa.
Lack of sickling in peripheral blood is evident in mice with sickle cell trait and
comparable to wild-type mice.

Using the contrast between TdT fluorescence reporter and injected dextran
conjugated

with

fluorescein

isothiocyanate

(FITC),

we

evaluated

the

microvasculature integrity and blood flow in the renal inner medulla. Mice with
SCT had discontinuous and disorganized blood vessels, including significantly
shorter diameters (P < 0.0001) and lengths (P < 0.0001) of healthy blood vessels
(Figure 4A-C).
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Figure 4. Analysis of perfusion in SCT mice. (A) 3D image reconstruction of renal
epithelia (RFP) and FITC-dextran (GFP) in adult mice (n=4-5) with kidney-specific
CDH16Cre and conditional R26LSL-Tom shows hypoperfusion in the inner medulla of
mice with SCT. (B, C) Quantification of the diameter (B) and length (C) of the renal
blood vessels (10 vessels/image, 3 locations/vessel). P values were calculated by
student’s t test (average of single values/mouse).

To measure whether hypo-perfusion in blood vessels leads to hypoxia, we injected
Hypoxyprobe, which binds to tissue with oxygen tension less than 10 mm Hg (less
than the normal physiological oxygen tension seen in the inner medulla). The
results of this experiment confirmed that the microvascular changes we observed
earlier yielded significantly higher hypoxia in the renal inner medulla of SCT mice
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compared with wild-type controls (P < 0.0001) (Fig. 5A-B). Further stratification of
Hypoxyprobe quantification (Figure 5C) shows that the difference between wildtype an SCT is primarily seen in the right kidney. The reason for this predilection
for the right kidney is also seen in RMC patients, and could be explained by the
fact that the right renal artery is longer, thus experiencing greater resistances in
flow that can then lead to an increase in hypoxia and sickling as proposed by
Msaouel and colleagues (38). Similar to humans, our mouse models also have
longer renal right arteries (Figure 6), which may explain the higher hypoxia seen
in the right kidney. As we demonstrated, the presence of sickling RBCs further
exacerbates renal hypoxia by causing ischemia.
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Figure 5. Quantification of renal hypoxia and mouse kidney anatomy.

(A)

Hypoxyprobe (pimonidazole hydrochloride) was injected in the intraperitoneal
cavity of GEMM of SCT with kidney-specific CDH16Cre and conditional R26LSL-Tom
three hours prior to euthanasia and harvesting of kidneys. Kidneys were processed
and immunohistochemistry with the Hypoxyprobe antibody was used to show
hypoxia in the inner medulla of wild-type mice (top) and mice with SCT (bottom).
(B-C) Quantification of the optical density of horseradish peroxidase staining for
49

20x images was done using ImageJ. Comparisons were made between wild-type
(n=52) and SCT mice (n=31) (B). Additionally, quantification was stratified by
kidney laterality within SCT (left kidneys, n=8; right kidneys, n=18) and wild-type
(left kidneys, n=16; right kidneys, n=26) mice (C). Data are expressed as mean
value ± SD, with P value calculated by student’s t test.

Figure 6. Renal artery lengths in mice. (A) Gross anatomy of C57BL/6J mixed
background mouse showing difference in the lengths between the right and left
renal arteries. (B) Quantified difference in the length of left and right renal arteries
from six adult C57BL/6J mixed background mice. Data are expressed as mean
value ± SD, with P value calculated by student’s t test.

3.2 High-intensity exercise significantly increases in HIF1α activity in SCT
mice.
Previous reports in individuals with SCT have shown that high-intensity exercise
can result in complications. Therefore, we hypothesized that high-intensity
exercise related complications seen in patients with SCT are related to the
resulting ischemia and consequential hypoxia caused by sickling RBCs that we
validated in our previous mouse model experiments. To test whether increasing
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the intensity of exercise would worsen renal hypoxia among SCT mice, we
generated a GEMM of SCT by crossing the hα/hα::βS/βS strain with the
Gt(ROSA)26Sortm2(HIF1A/luc)Kael strain, allowing non-invasive monitoring of Hif1α
activity in response to hypoxia by measuring luciferase activity using IVIS (Figure
7).(105)

Figure 7. Schematic of GEMM of SCT with Hif1α oxygen-dependent degradation
domain fused to firefly luciferase, allowing non-invasive monitoring of Hif1α activity
in response to hypoxia using the in vivo imaging system (IVIS). The hα/hα::βS/βS
strain was crossed with the Gt(ROSA)26Sortm2(HIF1A/luc)Kael strain.

We evaluated wild-type and SCT mice with two different treadmill exercise
intensities: moderate-intensity exercise (12 meters/minute), which correlates with
65% to 70% VO2 max, and high-intensity exercise (15 meters/minute), which
correlates with approximately ≥80% VO2 max as previously established (75).
Luciferase fluorescence was measured prior to exercise, immediately after
exercise, and after one hour of rest (Figure 8).
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Figure 8. Schematic of exercise experiment indicating time-points at which Hif1αluciferase is measured using IVIS imaging systems.

When exposed to moderate-intensity exercise, there was a significant decrease in
Hif1α activation in the SCT mice for both the left (P = 0.048) and right (P = 0.02)
kidneys. However, there was no significant change in Hif1α activation in wild-type
mice (Figure 9).
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Figure 9. Moderate-intensity exercise. (A-B) IVIS imaging of wild-type (n=11) and
SCT (n=10) mice harboring the Hif1α oxygen-dependent degradation domain
fused to firefly luciferase before moderate-intensity exercise, immediately after,
and after one hour of rest. Two-way ANOVA and Tukey multiple comparison tests
were used to calculate the P values of the changes in Hif1α–luciferase activity in
adult SCT (n=10) and wild-type (n=11) mice after exercise and rest.
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However, high-intensity exercise resulted in significantly higher Hif1α activation
among SCT mice compared to wild-type (P = 0.005), which was most prominent
in the right kidney (P = 0.04) (Figure 10).
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Figure 10. High-intensity exercise. IVIS imaging of wild-type (n=11) and SCT
(n=10) mice harboring the Hif1α oxygen-dependent degradation domain fused to
firefly luciferase before high-intensity exercise, immediately after, and after one
hour of rest. Two-way ANOVA and Tukey multiple comparison tests were used to
calculate the P values of the changes in Hif1α–luciferase activity in adult SCT
(n=10) and wild-type (n=11) mice after exercise and rest.

As we described earlier, the higher tissue hypoxia in the right kidney of SCT mice
in the setting of high-intensity exercise might be explained by the fact that the right
kidney in humans has a proclivity to have hypoxia due to the longer length of the
right renal artery, which leads to greater resistance (42).

3.3 Evaluation of physical activity in patients with RMC.
To assess whether high-intensity exercise is associated with RMC, we evaluated
a total of 71 patients with RMC and 122 patients with other malignancies as
controls (Tables 3-5). Similar to prior studies, patients with RMC had sickle
hemoglobinopathy (predominantly SCT), the majority were male (69%) and of
African descent (86%), and the primary tumor was located in the right kidney three
times more frequently (76%) than the left (Table 3-4). Compared with matched
controls, patients with RMC had significantly higher rates of positive activity index,
reported exercise, athletic involvement, and military service (Table 3).
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Additionally, patients with RMC had significantly poorer ECOG performance
(“Eastern Cooperative Oncology Group” is a measure of functional status, with a
score of “0” meaning fully active, no performance restriction; and “1” meaning
strenuous activity restricted) status compared to controls (Table 3). We evaluated
the albumin levels obtained at the time of diagnosis as a surrogate measure of
cachexia (weight loss and muscle wasting) (106-108). No significant difference in
albumin level was found between RMC and control patients (Table 3). Together,
this data lead us to conclude that the higher activity score and SM seen in RMC
patients are not a result of overall better health in RMC patients compared to
matched controls. In fact, despite their lower ECOG score, RMC patients still
showed higher activity levels and SM, further supporting the notion that highintensity exercise preceded RMC, which has deteriorating effects on overall patient
wellness.

Table 3. Clinical characteristics of patients with RMC and matched control
genitourinary malignancies.
Variable

Median age (IQR)

RMC (n=71)

Matched

P

(n=122)

value

29.6 (23.2-

29.9 (23.8-

37.5)

39.6)

Biological sex, no. (%)

0.5
0.7

Male

49 (69)

87 (71.3)

Female

22 (31.0)

35 (28.7)

56

Race, no. (%)

<0.001

African American

61 (85.9)

47 (38.5)

White

7 (9.9)

66 (54.1)

Hispanic

2 (2.8)

4 (3.3)

Asian

1 (1.4)

5 (4.1)

71 (100)

0

<0.001

Sickle hemoglobinopathy, no.
(%)
Sickle cell trait

70 (98.6)

Sickle beta-thalassemia

1 (1.4)

Comorbidities, no. (%)
HTN

12 (16.9)

33 (27.1)

0.2

Other comorbidities

8 (11.3)

58 (47.5)

<0.001

ECOG, no. (%)

<0.001

0

15 (21.1)

78 (63.9)

1

42 (59.1)

41 (33.6)

2

10 (14.1)

2 (1.6)

3

4 (5.6)

1 (0.8)

Median BMI, kg/m2 (IQR)

27 (24.3-29.9)

Median albumin, g/dL (IQR)

4.3 (4-4.6)

4.4 (4.1-4.6)

0.3

Smoking history, no. (%)

15 (21.1)

56 (45.9)

0.001

Exercise history, no. (%)

36 (50.7)

18 (14.8)

<0.001

Athlete, no. (%)

24 (33.8)

5 (4.1)

<0.001
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27.1 (23.931.6)

0.7

Military, no. (%)

7 (9.9)

4 (3.3)

0.005

Activity index, no. (%)

47 (66.2)

20 (16.4)

<0.001

Table 4. Additional clinical characteristics of patients with RMC.
Variable

RMC (n=71)

Family history RCC, no. (%)

4 (5.6)

Presenting symptoms
Pain

55 (77.5)

Hematuria

39 (54.9)

Weight loss

19 (26.8)

Fever

1 (1.4)

Chills

1 (1.4)

Night sweats

3 (4.2)

Localized at diagnosis

8 (11.3)

Metastatic at diagnosis

63 (88.7)

T stage
T1-T2

66 (93.0)

T3-T4

3 (4.2)

Unknown

2 (2.8)

Max tumor diameter, median (IQR)

5.8cm (5-7cm)

RMC laterality
Right kidney

54 (76.1)
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Left kidney

17 (23.9)

Multiple metastatic locations

55 (77.5)

Nephrectomy

50 (70.4)

Table 5. Metastatic locations among patients with RMC and metastatic disease at
initial diagnosis.
Metastatic site

N=63 (%)

Retroperitoneal nodes

52 (82.5)

Lungs

45 (71.4)

Bone

15 (23.8)

Liver

14 (22.2)

Hilar LN

13 (20.6)

Soft tissue

5 (7.9)

Supraclavicular LN

4 (6.4)

Ipsilateral adrenal

4 (6.4)

Pancreas

2 (3.2)

Thyroid

2 (3.2)

Mesentery

1 (1.6)

Ovary

1 (1.6)

Spleen

1 (1.6)

Brain

1 (1.6)

Bowel

0
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Contralateral kidney

0

Contralateral adrenal

0

Table 6. Cancer type and stage for matched control patients.
Matched Patient

N = 122 (%)

Stage III, n (%)

Stage IV, n (%)

Testicular cancer

46 (37.7)

46 (100)

0

Renal cell carcinoma

46 (37.7)

13 (28.3)

33 (71.8)

Bladder cancer

21 (17.2)

4 (19.0)

17 (81.0)

Prostate cancer

9 (7.4)

0

9 (100)

Cancer Type

3.4 Prospective study of physical activity in RMC patients.
We prospectively gathered detailed information on the exercise activity of 7
additional patients with RMC seen at our institution (Tables 7-8). Consistent with
our retrospective findings, the majority of patients (71%) reported frequent, highintensity exercise defined as ≥80% of maximal heart rate during each exercise
session (Table 8).

Table 7. Clinical characteristics of prospectively evaluated patients with RMC.
Variable

N=7

Median age (IQR)

28 (17-43)

Biological sex, no. (%)
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Male

4 (57)

Female

3 (43)

Race, no. (%)
African American

7 (100)

Sickle hemoglobinopathy, no. (%)
Sickle cell trait

6 (86)

Sickle beta-thalassemia

1 (14)

Comorbidities
HTN

5 (71)

Other

4 (57)

ECOG, no. (%)
0

0 (0)

1

5 (71)

2

2 (29)

Median BMI, kg/m2 (IQR)

20.1 (18.6-28)

Median albumin, g/dL (IQR)

4.2 (3.8-4.5)

Smoking history, no. (%)

2 (29)

Exercise history, no. (%)

5 (71)

Athlete, no. (%)

5 (71)

Military, no. (%)

0 (0)

Activity index, no. (%)

5 (71)

RMC laterality, no. (%)
Right kidney

3 (43)
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Left kidney

4 (57)

Table 8. Prospectively collected exercise history of seven patients with RMC.

ID

1

Exercise
intensity

High

Exercise
time

Participation

per prior to RMC

week
≥3 hours

diagnosis

Exercise
Description
Softball and

>3 years

swimming

Primary
tumor
laterality
Left

Basketball and
2

High

≥2 hours

>3 years

frequent gym

Right

exercise
3

High

≥2 hours

Basketball, soccer,

>3 years

4

High

≥3 hours

>3 years

5

None

None

None

weightlifting
Professional
athlete
Sedentary lifestyle

Right

Left
Left

Track, martial arts,
6

High

≥3 hours

>3 years

and frequent gym

Right

exercise
7

None

None

None

Sedentary lifestyle
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Left

3.5 Epidemiological study of RMC patients with active military duty
compared to general SCT population in the United States (U.S.).
We validated these findings in a separate epidemiologic comparison group by
looking at the proportion of all black individuals with SCT who serve in the U.S.
military, hypothesizing that the intense physical activity of military duty may
increase the risk of RMC. We found that a higher proportion (OR 8.4, 95% CI 3.218.4, P < 0.0001) of black patients with RMC (7/61, 11%) have served in the U.S.
military than would be expected compared to the similarly aged black population
with SCT in the U.S. (Figure 11).

Figure 11. Estimated proportion of black individuals with SCT aged 20 to 40 years
in the United States military (1.5%) compared to the proportion of similarly aged
black patients with SCT in the RMC cohort (11%).

3.6 Assessment of skeletal muscle (SM) in RMC patients.
To measure whether RMC patients have a higher skeletal muscle (SM) area as a
result of high-intensity exercise, the SM of patients was measured compared to
matched control patients with other malignancies. Our analysis showed that
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patients with RMC had significantly higher SM surface area (median 59.3 cm2/m2,
IQR 50.2-69.9 cm2/m2) compared with controls (median 52.4 cm2/m2, IQR 45.059.1 cm2/m2) (P = 0.001) (Figure 12). Race, age, and biological sex were identified
as potential confounders for the associations between RMC diagnosis, exercise
activity, and SM surface area (Figure 12). Although it was not identified as a
potential confounder, we performed a sensitivity analysis where albumin, a
surrogate for cachexia,(106) was included as a covariate in our multivariable model
for SM, and SM remained significantly associated with RMC diagnosis (Table 10).
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Figure 12. Clinical evaluation of physical activity for RMC and control patients. (A)
Representative axial CT images from five RMC (top) and matched control (bottom)
patients analyzed for skeletal muscle (SM) surface area (red) and subcutaneous
adipose (green). (B-C) Dot plots of SM (top) and subcutaneous adipose (bottom)
surface area.
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Table 9. Odds ratio of reported exercise and skeletal muscle.
Odds Ratio 95% CI

P value

Model 1
Reported exercise
history

10.4

4.5-23.9 <0.001

1.04

1.01-1.07 0.03

Model 2
Skeletal muscle
surface area

Table 10. Multivariable model including albumin evaluating the association
between standardized skeletal muscle surface area and diagnosis of RMC.
Variable
Skeletal muscle surface
area
Age

Odds Ratio

95% CI

P value

1.04

1.00-1.08

0.04

0.99

0.95-1.02

0.5

0.7-5.1

0.2

Gender
Male

Ref

Female

1.9

Race
Black

Ref

Caucasian

0.08

0.03-0.2

<0.001

Hispanic

0.4

0.06-2.2

0.3
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Asian

0.3

0.03-2.5

0.2

Albumin

0.4

0.2-0.98

0.045

The results of the first part of this study strongly demonstrates that high-intensity
exercise is associated with RMC in individuals with SCT, identifying for the first
time a modifiable risk factor for developing RMC. Additionally, these results
suggest that the missing link between SCT and the loss of the tumor suppressor,
SMARCB1 seen in RMC is hypoxia. Therefore, the second part of this study will
investigate whether there is an evolutionary pressure towards SMARCB1 loss in
the setting of hypoxia.

Part 2: SMARCB1 is ubiquitinated and degraded in hypoxia.
3.7 Characterization of RMC patient samples.
The absence of SMARCB1/INI1/SNF5 protein in patient samples using IHC is one
of the parameters used to diagnose RMC tumors in the clinic. Therefore, the lack
of SMARCB1 protein is a well-known feature of RMC (Figure 13). In addition, our
group also showed that RMC is characterized primarily by deep deletions and
translocations of SMARCB1 (40). However, we also surprisingly showed that
adjacent normal kidneys in patients with RMC also have initial loss of SMARCB1
protein as demonstrated using IHC (Figure 14). Quantification of IHC patient
samples from clear cell RCC (ccRCC) and other RCCs in comparison to RMC
patient samples showed that RMC patient samples have a greater percentage of
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cells with SMARCB1 loss, further supporting the notion that SMARCB1 loss is
specific to SCT, purportedly due to the renal hypoxia caused by SCT (Figure 15).

Figure 13. RMC IHC with SMARCB1 loss and massive neutrophil invasion.
SMARCB1 is indicated in blue (Alkaline phosphatase) staining and EIF2-alpha is
indicated in horse radish peroxidase (HRP) 3,3'-Diaminobenzidine (DAB) staining.
The arrows indicate SMARCB1 loss. Image is 100X.
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Figure 14. RMC adjacent kidneys with SMARCB1 loss characterized using IHC
analysis. SMARCB1 is indicated in blue (Alkaline phosphatase) staining and EIF2alpha is indicated in horse radish peroxidase (HRP) 3,3'-Diaminobenzidine (DAB)
staining. The arrows indicate SMARCB1 loss.

Figure 15. Quantification of SMARCB1 loss in IHC patient samples from RMC,
ccRCC, and other RCCs. Ten 20x images/patient sample (n=10) was quantified.

Further analysis using FISH revealed that approximately 33% of adjacent normal
kidney in RMC patient samples also have initial monosomy (Figure 16-17). All
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patients had SCT, further supporting our hypothesis that SMARCB1 loss is
associated with hypoxia caused by sickling RBCs. RNA-sequencing analysis of
patient samples compared to adjacent normal kidneys also show that hypoxia
genes are enriched in RMC tumors (Figure 18). Msaouel and colleagues also
showed in their RMC patient cohorts that hypoxia gene signatures are enriched in
RMC patient tumors compared to normal adjacent kidneys (40).

Figure 16. Schematic of FISH analysis. (A) SMARCB1A-20-GROR break apart
probe (Empire Genomics) containing an orange telomeric label and a green
centromeric label was used to label SMARCB1 gene. Partial loss of SMARCB1
was defined as loss of either green or orange probes. (B) Schematic of different
possible events seen with FISH analysis.
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Figure 17. FISH analysis (A) FISH analysis of adjacent normal kidneys. (B)
Quantification of n=10 RMC patient samples showing initial monosomy of
SMARCB1 in adjacent normal kidneys (all patients have SCT).
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Figure 18. RNA-sequencing analysis of RMC tumors compared to adjacent normal
kidneys. (A) GSEA analysis showing enrichment of hypoxia pathways, and (B)
Volcano plot showing enrichment of hypoxia pathway genes.

3.8 SMARCB1 is degraded in hypoxia.
Together, these results lead us to hypothesize that the renal hypoxia we showed
in part 1 of this study may be leading to the degradation of SMARCB1 protein in
the epithelial cells of the renal collecting ducts. A previous study in synovial
sarcoma showed that a fusion oncoprotein called SS18-SSX was responsible for
ejecting SMARCB1 (also called BAF47 in the study) from the mSWI/SNF complex,
leading to its ultimate degradation (109). This study demonstrated how SMARCB1
could potentially be ubiquitinated and degraded. To investigate this further, we
used an established epithelial cell line derived from the collecting ducts (IMCD-3)
of mice for in vitro studies. Cells were placed in a hypoxia chamber at 1% oxygen
level for time intervals of 24, 48, and 72 hours. The oxygen level of the kidney
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medulla is approximately 2%; therefore, 1% oxygen represents an “ischemic” or
extreme hypoxic state of the kidney (43).

Protein analysis of Smarcb1 levels using immunoblotting showed that Smarcb1
levels in IMCD-3 cells were gradually decreasing after extended periods of
exposure to extreme hypoxia (1%) in time intervals of 0, 24, 48, and 72 hours, with
72 hours having the most extreme phenotype (Figure 19). Microscope images of
IMCD-3 cell after increasing exposure to hypoxia shows no obvious change in the
morphology of IMCD-3 cells (Figure 20).

Figure 19. Immunoblotting of loss of Smarcb1 protein and gradual increase in
Hif1α protein in IMCD-3 cells with increasing exposure to hypoxia.
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Figure 20. IMCD-3 cells morphology after increasing exposure to hypoxia.

Re-oxygenation experiments in which cells were moved to normal oxygen levels
(18-20% oxygen) after being subjected to 24 hours of hypoxia (1% oxygen)
showed that Smarcb1 levels returned to about 50% of original normoxia levels after
one hour of re-oxygenation at 18-20% of oxygen (Figure 21A-B). After
reoxygenation for one hour, there was no obvious change in morphology in IMCD3 cells (Figure 21C). However, 48 hours and 72 hours of hypoxia had more
detrimental effects on IMCD-3 cells. After 48 hours of exposure to hypoxia, it took
almost 24 hours for Smarcb1 protein levels to return >50% of original protein levels
at normoxia (Figure 22A-B). Also, the cells appeared stressed and damaged after
re-oxygenation (Figure 22C). As for 72 hours of re-oxygenation, cells did not
survive.
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Figure 21. IMCD-3 cells re-oxygenated after 24 hours of hypoxia. (A) Smarcb1
protein band was normalized to corresponding Vinculin protein band using ImageJ
FIJI. Bands 0-60 minutes were then compared to Nx (normoxia) protein band for
quantification in (B). Microscope images of IMCD-3 cells after 20, 30, and 60
minutes of re-oxygenation (C). There is no obvious change in morphology in IMCD3 cells.
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Figure 22. IMCD-3 cells re-oxygenated after 48 hours of exposure to hypoxia. (A)
Smarcb1 protein band was normalized to corresponding Vinculin protein band
using ImageJ FIJI. Bands 0-24 hours were then compared to Nx (normoxia) protein
band for quantification in (B). Microscope images of IMCD-3 cells after 0, 16, and
24 hours of re-oxygenation (C). There is no obvious change in morphology in
IMCD-3 cells.

To further assess whether Smarcb1 is being degraded in hypoxia, we next
performed cycloheximide (CHX) chase experiments. A previous work by Kadoch
and Crabtree showed that the half-life of Smarcb1 based on a cycloheximide chase
assay is approximately 10 hours after the addition of CHX at normal conditions,
and they also showed that the addition of MG-132 could rescue the protein levels
>85%, which is indicative of proteasome-mediated degradation (109). Similarly,
we showed using CHX treatment that Smarcb1 is protein levels are reduced after
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CHX treatment in both normoxic and hypoxic conditions. The half-life of Smarcb1
degradation is approximately 12 hours in normoxic conditions (Figure 23), which
is similar to what Kadoch and Crabtree observed in normal conditions (109).
However, the half-life of Smarcb1 was reduced by half to 6 hours in hypoxic
conditions, indicating an accelerated degradation in hypoxic conditions (Figure
24). In both conditions, the addition of MG-132 can rescue protein levels >85% of
original levels (Figure 23, Figure 24). Altogether, this data indicates that
proteasome-mediated degradation of Smarcb1 is occurring in hypoxia.

Figure 23. Cycloheximide chase assay of IMCD-3 cells in normoxia. (A)
Cycloheximide (CHX) chase experiment with MG-132 protein rescue after 24
hours of growth in normoxia. CHX chase experiment shows that the half-life of
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Smarcb1 at normoxic conditions is approximately 12 hours. Smarcb1 protein levels
were compared to Smarcb1 protein levels at normoxic conditions without the
addition of CHX. Experiments were performed in triplicates (B). The (*) indicates a
P-value <0.05 as calculated by Student’s t-test in GraphPad.

Figure 24. Cycloheximide chase assay of IMCD-3 cells in hypoxia. (A)
Cycloheximide (CHX) chase experiment with MG-132 protein rescue after 24
hours of growth in hypoxia. CHX chase experiment shows that the half-life of
Smarcb1 at hypoxic conditions is approximately 6 hours. Smarcb1 protein levels
were compared to Smarcb1 protein levels at hypoxic conditions without the
addition of CHX. Experiments were performed in triplicates (B). The (*) indicates a
P-value <0.05 as calculated by Student’s t-test in GraphPad.
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3.9 Generation of ex vivo SMARCB1-/- renal tumor cell line in C57BL/6J
mice.
Since ubiquitin (UB) is often involved in proteasome-mediated degradation, we
next sought to explain whether Smarcb1 is ubiquitinated in hypoxia. First, we
started by generating a mouse kidney tumor cell line using CRISPR/Cas9 gene
editing technology to knockout Smarcb1 (Figure 25). Knockout of Smarcb1 in vitro
in normal epithelial cells, such as IMCD-3, is difficult because Smarcb1 is cell
essential as others have demonstrated (19). Clones with Smarcb1 knockout will
usually senesce and die. Carugo and colleagues were able to overcome the
embryonic lethality of Smarcb1 knockout by generating mosaic mouse models of
MRT using CRISPR/Cas9 gene editing technology (28). Similarly, we used
CRISPR/Cas9 gene editing technology to generate a somatic mosaic genetically
engineered mouse models (SM-GEMMs) with kidney specific ablation of Smarcb1,
Cdkn2a, Cdkn2b, and Trp53. Tumor suppressors, Cdkn2a, Cdkn2b, and Trp53
were included in addition to Smarcb1 in the sgRNA package in order to decrease
time of onset and increase penetrance.

Using CRISPR Cas9 gene editing technology, we injected orthotopically
sgSmarcb1 into the right kidneys of C57BL/6J pure background mice with Rosa26Cas9 knockin (Figure 25). The Rosa26-Cas9 knockin mice have constitutively
active Cas9 with a GFP reporter. Therefore, it is critical to carefully inject guides
directly into the kidneys of mice and avoid leakage of virus. Twelve mice were
injected, and all twelve mice developed aggressive kidney tumors within two
months. Another study from our group showed that sgRNA package containing
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only Cdkn2a, Cdkn2b, and Trp53, which was used as a negative control, yielded
only indolent tumors characterized by low penetrance and long latency (110).
Therefore, the aggressive features observed with sgRNA package containing
Smarcb1 in addition to Cdkn2a, Cdkn2b, and Trp53 can be attributed to Smarcb1
ablation. Histological evaluation of renal tumors showed rhabdoid-like features that
are characteristic of Smarcb1 knockout (Figure 26).

Figure 25. Schematic of sgSmarcb1 design. (A), and results of T7 endonuclease
assay (B). Schematic of orthotopic kidney injection into C57BL/6J.129(Cg)Gt(ROSA)26Sortm1.1(CAG-cas9*,-EGFP)Fezh/J mice containing Rosa26-Cas9 knockin on
C57BL/6J.
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Figure 26. Histological evaluation of renal tumor cell lines generated from sgRNA
for Smarcb1, Cdkn2a, Cdkn2b, and Trp53 injected into kidneys of C57BL/6J mice
with Rosa26-Cas9 knockin. Tumor tissue was stained with hematoxylin and eosin.

Tumor cell lines were then prepared from tumors and used for further ex vivo
studies (Figure 27A-B). Immunoblotting analysis of renal tumor cell line confirmed
that cell lines are negative for Smarcb1 (Figure 27C). Also, 1X106 Smarcb1-/- renal
tumor cell lines were transplanted subcutaneously into pure background C57BL/6J
mice, and easily developed into tumor masses after approximately 2 weeks after
initial transplantation (Figure 27D).
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Figure 27. Characterization of Smarcb1-/- renal tumor cell lines derived from
sgRNA for Smarcb1, Cdkn2a, Cdkn2b, and Trp53 injected orthotopically into
kidneys of C57BL/6J mice with Rosa26-Cas9 knockin. (A) Example of renal tumors
that developed from somatic mouse model using CRISPR Cas9 gene editing
technology. (B) Microscopic images of tumor cell lines prepared from spontaneous
tumors generated from somatic mouse model. (C) Immunoblotting of two tumor
cell lines derived from somatic mouse models showing successful Smarcb1
knockout. (D) Subcutaneous transplantation of Smarcb1-/- renal tumor cell lines
into pure background C57BL/6J mice. Tumors shown were allowed to grow for
about 2 weeks.
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3.10 SMARCB1 is ubiquitinated in hypoxia and K62 mutation can prevent
the degradation of SMARCB1 in hypoxia.
To further understand the mechanism of protein degradation of Smarcb1 in
hypoxia, we re-constituted wild-type Smarcb1 in Smarcb1-/- renal tumor cell lines
previously described. Immunoprecipitation (IP) experiment was then used to
assess whether Smarcb1 was ubiquitinated in hypoxia. Smarcb1-/- renal tumor
cells and Smarcb1+/+ renal tumor cells were placed in 24 hours of normoxia and
hypoxia (1% oxygen) and treated with 10 μM of MG-132 for six hours prior to lysing
cells for further IP analysis. Anti-SMARCB1 (Bethyl laboratories) was then used to
precipitate Smarcb1 protein, and immunoblotting analysis was used to assess both
SMARCB1 (BD laboratories) and UBIQUITIN (Cell Signaling) protein expressions.
IP analysis demonstrates that Smarcb1 is specifically ubiquitinated in hypoxia,
further supporting the notion that Smarcb1 is degraded via a proteasome-mediated
degradation pathway in hypoxia (Figure 28).
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Figure 28. Immunoprecipitation (IP) analysis of Smarcb1 ubiquitination after 24
hours of hypoxia treatment. 5 μg of anti-Smarcb1 (Bethyl laboratories) was used
to precipitate Smarcb1 after treatment with normoxia and hypoxia. Immunoblotting
was used to assess whether Ubiquitin protein increased after exposure to hypoxia.

To further investigate the mechanism of protein degradation, we proceeded to use
site-directed mutagenesis (SDM) to mutate lysine residues that have been shown
to be ubiquitinated on Smarcb1 by previous studies (Table 2). We also included
known hotspot mutations (R377H, K363, K364) in the study. Mutant Smarcb1
proteins and wild-type Smarcb1 were then re-constituted in Smarcb1-/- renal tumor
cell line. Cells were placed 48 hours of hypoxia (we wanted to measure the
timepoint with the greatest degradation) and normoxia and lysed for
immunoblotting for Smarcb1 protein levels. Protein expression of Smarcb1
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mutants and wild-type Smarcb1 protein levels were compared to Smarcb1 levels
in normoxia (Figure 29). Only experiments that showed residual Smarcb1 protein
levels are shown in Figure 29. Other mutants had almost no quantifiable protein.
Overall, wild-type Smarcb1 protein is usually degraded to approximately <50% of
original protein levels seen in normoxic conditions. Out of all of the mutants, K62R
showed the most significant rescue of Smarcb1 protein levels in hypoxia with >50%
of protein expressed (Figure 29).

Figure 29. Immunoblotting of Smarcb1 protein expression after treatment with 48
hours of hypoxia (1% oxygen) in re-constituted wild-type Smarcb1 and Smarcb1
lysine mutants. Smarcb1 protein band was normalized to corresponding Vinculin
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protein band using ImageJ FIJI software. Smarcb1 mutants were compared to
Smarcb1 levels at normoxic conditions and graphed using a bar plot.

Next, we investigated whether K62R mutation had any effect on cell survival in
hypoxic conditions. Cells with wild-type Smarcb1 re-constituted were compared to
cells with re-constituted Smarcb1 with K62R mutation in both normoxic and
hypoxic conditions using clonogenic assay. Cells were allowed to grow at said
conditions for approximately seven days, before crystal violet was dissolved and
quantified. The results of this experiment demonstrated that K62R Smarcb1
mutant had no significant effect on renal tumor cell growth in normoxic conditions.
However, K62R Smarcb1 mutant re-constitution significantly decreased the growth
of renal tumor cells in hypoxic conditions in comparison to Smarcb1-/- tumor cells
and wild-type Smarcb1 (Figure 30). These results suggest that Smarcb1
degradation specifically in the context of hypoxia is conferring a survival advantage
to renal tumor cell lines. Therefore, preventing the degradation of Smarcb1 has no
significant effect in normoxia, but is detrimental to cell proliferation and survival in
hypoxia.
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Figure 30. Clonogenic formation assay of Smarcb1-/- renal tumor cells in
comparison to cells re-constituted with wild-type Smarcb1 or K62R mutant. Cells
were grown in either normoxia (A) or hypoxia (B) for approximately seven days
before cells are stained with crystal violet (CV). CV is then dissolved in 10% acetic
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acid and quantified as shown above. P-values were calculated with Student’s ttest in Prism GraphPad.

3.11 SMARCB1 loss confers a survival advantage for renal tumor cells in
hypoxia.
We next sought to investigate whether the loss of Smarcb1 confers a survival
advantage for renal tumor cells in hypoxia. Re-constitution of wild-type Smarcb1
in Smarcb1-/- did not cause any obvious change in cell morphology or growth based
on clonogenic assay at normoxic conditions with both high glucose (25 mM, DMEM
concentrations) and low glucose (5 mM) medias (Figure 31).

However, re-

constitution of wild-type Smarcb1 in hypoxic conditions (1% oxygen) decreased
the growth of cells in high glucose media (25 mM), suggesting that the loss of
Smarcb1 is beneficial for cell survival in hypoxia in the presence of abundant
glucose (Figure 31). Both Smarcb1-/- cells and Smarcb1+/+ cells did not grow well
in hypoxia in low glucose, suggesting that glucose is the primary carbon source for
proliferating renal tumor cells in hypoxia, but not in normoxia (Figure 31).
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Figure 31. Clonogenic assay of Smarcb1-/- mouse renal tumor cells versus the
same cells with re-constituted wild-type Smarcb1+/+. Cells were grown for
approximately seven days in either normoxia in the presence of abundant (25 mM)
or low glucose (5 mM) or hypoxia (1% oxygen) in the presence of abundant
glucose (25 mM) or low glucose (5 mM). Cells were then stained with 0.5% crystal
violet (CV) for one hour.

Previous clinical studies have demonstrated that RMC, unlike other renal clear cell
cancers, does not respond to anti-VEGF tyrosine kinase inhibitors (TKIs) (67). We
hypothesized that this insensitivity to anti-VEGF inhibitors is caused by the fact
that Smarcb1 confers a survival advantage to cells in hypoxia. Therefore, the
inhibition of angiogenesis, which promotes a more hypoxic environment, is
theoretically ineffective against RMC, a SMARCB1-deficient tumor.
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To investigate this hypothesis, RMC219, a RMC human tumor cell line that was
established from a patient-derived xenograft in a previous study (85), was infected
with

tetracycline-inducible

pIND20-fSNF5-HA

vector.

Upon

addition

of

Doxycycline, SMARCB1 would be re-constituted in RMC219 cells (Figure 32). An
empty vector was used as the negative control. There was no significant difference
in morphology for RMC219 cells deficient in SMARCB1 (EV) compared to RMC219
with re-constituted SMARCB1 (OE). However, cells with re-constituted SMARCB1
do appear to cluster more readily into epithelial-like colonies, while RMC219 with
SMARCB1 deficiency ha more mesenchymal-like in morphology (Figure 32).

RMC219-tet-inducible SMARCB1 (OE) and RMC219-tet-empty (EV) were cultured
without Doxycycline (DOX) and 1x106 cells were transplanted subcutaneously into
NSG mice. After allowing cells to grow into a tumor mass for one week, mice were
then placed on DOX water. After three days, we began to treat cohorts of mice
with 30 mg/kg of Axitinib (Selleckchem), a selective anti-VEGF inhibitor and
equivalent vehicle for two weeks daily. Measurement of final tumor mass showed
that RMC219 deficient in SMARCB1 were not sensitive to treatment with Axitinib
and is not significantly different from the vehicle group (Figure 33). However,
RMC219 cells re-constituted with wild-type SMARCB1 had significantly reduced
growth compared to the same cells treated with vehicle (Figure 33). Interestingly,
re-constitution of wild-type SMARCB1 alone (OE) treated with vehicle was not
significantly different from SMARCB1-deficient groups. Altogether, these results
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showed that SMARCB1 loss conferred a selective survival advantage to cells in
hypoxic conditions.

Figure 32. RMC219-tet-inducible (OE) and RMC219-tet-empty (EV) cell line. (A)
Immunoblotting analysis of SMARCB1 protein expression in RMC219-tet-empty
vector (EV) and RMC219-tet-inducible SMARCB1 (OE) after 3 days of treatment
with 2 μg of Doxycycline (DOX). (B) Microscope images of RMC219-tet-inducible
cell lines, EV and OE, after 3 days of treatment with DOX. There is no significant
difference in morphology.
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Figure 33. Final tumor mass of RMC219-tet-inducible cell lines that were injected
subcutaneously (SQ) into NSG mice. Each dot represents one mouse. Tumors
were allowed to grow off of DOX until they reached 100 cm3 before mice were put
on DOX water and treated with Axitinib or vehicle. (A) Final tumor mass (g) of SQ
tumors. RMC219 with re-constituted SMARCB1 was sensitive to Axitinib
treatment, while RMC219 that was negative for SMARCB1 was resistant to
Axitinib. P-value was calculated with student’s t-test using Prism GraphPad.
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Chapter 4. Discussion and Future Directions
RMC is a lethal disease with limited therapeutic options. Additionally, it affects
predominantly individuals with SCT, whom account for approximately 300 million
people in the world. Other than SCT, there are no other known risk factors for
developing RMC, and it has been an anomaly as to why some individuals with SCT
develop RMC while most individuals do not. Therefore, there is a great need to
better explain the pathogenesis of RMC in order to develop improved therapeutic
interventions and prevent RMC altogether.

In the first part of our study, we demonstrated using genetically engineered mouse
models of SCT that there is hypo-perfusion in the renal medulla of mice with SCT
(Figure 4). We then showed that the hypo-perfusion caused by sickling RBCs
consequentially caused renal hypoxia (Figure 5). Together, these results
demonstrated the negative consequences of sickling RBCs. Although, the inner
renal medulla is physiologically hypoxic (oxygen tension ~10 mm Hg), normal
RBCs that do not sickle are not affected by these stressful physiological conditions.
However, RBCs with the HbS mutation are vulnerable to sickling under stress like
hypoxia. Therefore, the microenvironment of the inner medulla, which is
physiologically hypoxic, becomes a region that is conducive to sickling. As we
showed in our mouse model of SCT, the peripheral blood of SCT mice does not
contain any sickling RBCs, making them similar to their wild-type counterparts
(Figure 3). The sickling RBCs are primarily seen in the renal compartments,
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particularly the medullary region of the kidney (Figure 2), further confirming our
hypothesis that SCT causes renal ischemia.

In normal conditions, ischemia would be resolved quickly by the body’s natural
homeostatic mechanism. However, in the presence of SCT, this process can be
inhibited as a result of the vaso-occlusion events occurring inside the renal
medulla. Much like a traffic accident, one incident can lead to a traffic jam that
stops the entire freeway from moving; the longer it takes to clear the accident, the
larger the buildup of traffic. The likelihood of healthy RBCs causing a “traffic jam”
is lower in the renal medulla because the RBCs are healthy and pliable. Whereas,
the likelihood of HbS RBCs sickling and occluding renal vessels is much higher
due to their proclivity to sickle under stress. Therefore, the chances of a rare event
occurring are compounded in the presence of SCT.

However, it was not understood why only some individuals with SCT develop RMC,
while most do not. Evaluation of our uniquely large cohort of RMC patients showed
that RMC patients frequently reported participation in high-intensity exercise based
on case-control analysis (Figure 8). We also found that patients with RMC more
frequently participated in active military duty in comparison to the general U.S.
population of black SCT individuals (Figure 11). Analysis of the skeletal muscle
(SM) surface area of patients with RMC compared to matched control patients also
showed that RMC patients had significantly higher SM surface area, even though
they had poorer ECOG scores (Figure 12).
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These observations lead us to hypothesize that high-intensity exercise might be a
risk factor for developing RMC. To test this hypothesis, we generated a mouse
model with Hif1α-Luciferase that would enable in vivo imaging of Hif1α activity, a
measure of hypoxia levels. Leveraging this mouse model, we asked the question
whether high-intensity exercise exacerbated renal hypoxia, which is known to be
cytotoxic and stressful for cells. Our studies demonstrated that moderate-intensity
exercise appears to significantly reduce renal hypoxia in SCT mice (Figure 9).
However, high-intensity exercise significantly increased renal hypoxia in SCT
mice, particularly in the right kidney (Figure 10).

The results of this experiment demonstrated the potentially detrimental effects of
high-intensity exercise in the presence of SCT. Again, our bodies are continuously
resolving potentially harmful ischemic/hypoxic events routinely. However, referring
again to our analogy about the traffic jam, the presence of SCT compounds the
likelihood of a rare event happening due to its proclivity to sickle under stress. Also,
not only are they more inclined to sickle and cause ischemic/hypoxic events, but
they are also slower to resolve, leading to chronic hypoxia as opposed to acute
hypoxia. Our studies show that one hour of rest after both low- and high-intensity
exercise could resolve hypoxia levels back to basal conditions. This data highlights
the importance of incorporating longer periods of rest in between physical activity,
particularly for individuals with SCT. It also alludes to the dangers of continuous
high-intensity exercise without proper respite, which could lead to a prolonged or
chronic renal hypoxia.
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In the SCT community, it has long been known that high-intensity exercise can
lead to complications. However, the connection between high-intensity exercise
and RMC, which was described as the seventh sickle cell nephropathy (32), has
never been shown through evidence-based research. Our study in both animal
models and patient studies demonstrated that high-intensity exercise is associated
with RMC and renal hypoxia.

Study limitations:
We have identified for the first time a potential risk factor for RMC, aside from SCT.
However, the major limitation of the clinical study is that it is mostly observational
in nature. Regardless, our inferences were strengthened by our multidimensional
approach that combined both case-control and retrospective evaluation of physical
activity in our uniquely large cohort of RMC patients with experiments in mouse
models for SCT.

To limit experimenter bias in our clinical study, RMC and matched controls used
for this study were evaluated using the exact same approach and are from the
same department and time period. SM surface area measurements in RMC
patients compared to matched control patients were obtained objectively,
demonstrating that RMC patients had significantly higher SM surface area
compared with matched controls. This trend remained consistent even after
controlling for confounders such as age, gender and race through case-control
design and multivariable regression analyses. Cachexia was also considered as a
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potential cofounder. However, if cachexia was truly biasing the results, we would
expect to see less SM surface area in RMC patients because RMC is one of the
deadliest genitourinary malignancies with sarcopenia quickly manifesting following
diagnosis (41, 67). The distinctive aggressiveness associated with RMC

is

mirrored by the significantly worse performance status as measured by ECOG that
we found in patients with RMC compared with matched controls. Additionally, there
was no significant difference in serum albumin, which is associated with cachexia
and mortality (107, 108), between RMC and matched controls. Furthermore,
images used to quantify muscle and adipose tissue were obtained prior to the
initiation of systemic therapy in order to avoid the detrimental effects of therapy on
anthropometric measures. Our epidemiologic analysis of the proportion of black
patients with RMC serving in the U.S. military compared with what would be
expected among similarly aged black men with SCT in the U.S again showed a
significant association between RMC and high-intensity exercise. Ongoing
prospective interrogation of additional patients with RMC continues to show a
pattern of high-intensity exercise in most patients.

Our clinical observations were further supported with mouse models with SCT
generated in our lab. Most notably, our studies showed that renal hypoxia
significantly increased predominantly in the right kidney following high- but not
moderate-intensity exercise, which is consistent with the right kidney dominance
of RMC (42). The major limitation of our GEMM experiments is that we did not
generate RMC tumors from these models. This is not unexpected because RMC

97

is a rare tumor in general, and this rare event is difficult to capture within a
reasonable cohort size of mice. Also, we anticipate that less than 1% of the mice
with SCT would develop RMC even after chronic exposure to high-intensity
exercise.

Overall, we have shown that there is a strong association of high-intensity exercise
with RMC in both clinical and animal model studies. However, more work is needed
to better understand the underlying biological mechanisms linking hypoxia to
tumorigenesis in the context of RMC. In this part two of this study, we began to
investigate the relationship between hypoxia and the loss of the tumor suppressor,
SMARCB1, that is seen in RMC.

In part two of this study, we demonstrated using renal mouse cell lines that
SMARCB1 is ubiquitinated and degraded in hypoxia. Other studies have
speculated that SMARCB1 is possibly ubiquitinated for proteasome-mediated
degradation (109). However, our study confirmed these speculations and
additionally showed that SMARCB1 is specifically ubiquitinated and degraded in
hypoxia, but not in normoxia. We performed a cycloheximide chase experiment in
both normoxia and hypoxia, and confirmed that the half-life of SMARCB1 in normal
conditions was approximately 12 hours as shown in previous studies (109).
However, we showed that the half-life of SMARCB1 was reduced to approximately
6 hours in hypoxia conditions (Figure 24), showing accelerated proteasomemediated degradation in hypoxia. We also demonstrated that mutating lysine
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residue K62 prevented the degradation of Smarcb1 in hypoxia, leading to
compromised clonogenicity in hypoxia (Figure 30).

These results suggest that the degradation of SMARCB1 is a physiological
response to stressful conditions such as hypoxia/anoxia that the cells might
experience in the inner medulla of the kidney. This finding is further confirmed by
the fact that adjacent normal kidneys in patients with SCT also have initial loss of
SMARCB1 protein (Figure 14). However, the fact that SMARCB1 loss drives
tumorigenesis in RMC leads us to speculate that prolonged loss of SMARCB1 is
maladaptive, leading to catastrophic consequences. As we have shown, SCT can
exacerbate and prolong hypoxia/anoxia in the renal medulla. Therefore, this
stressful microenvironment may be selecting for cells with SMARCB1 loss, which
initially confer a survival advantage as we have shown. However, SMARCB1 also
has tumor suppressor functions in cells, so its loss can also drive tumorigenesis.

Using CRISPR/Cas9 gene editing technology, we showed that knocking out
Smarcb1 leads to aggressive renal tumors with 100% penetrance (Figure 27). We
also showed in transplant mouse models with RMC219-tet-inducible SMARCB1
that the re-constitution of SMARCB1 increased the sensitivity of RMC219 to a
VEGF-inhibitor, Axitinib, while SMARCB1 deficient tumor cells were insensitive,
further supporting that SMARCB1-deficiency is protective to cells in hypoxia
(Figure 33).
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Altogether, our results elucidate for the first time the link between SCT and
SMARCB1 loss seen in RMC patients (Schematic 2). We have shown that SCT
leads to ischemia and consequentially chronic hypoxia (Figure 4, Figure 5). In
addition, we demonstrated for the first time that Smarcb1 is ubiquitinated and
undergoes proteasome-mediated degradation specifically in hypoxia (Figure 28).
Also, we have identified for the first time high-intensity exercise as a potential risk
factor for developing RMC.

Schematic 2. The pathogenesis of RMC.
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Future directions:
Although, our work has uncovered many new important findings, there is still much
more work needed to further elucidate the molecular underpinnings of SMARCB1
and hypoxia. For instance, although we have shown that SMARCB1 loss conferred
a survival advantage in terms of growth in hypoxia, we still do not understand what
molecular mechanisms are driving this selection process. Understanding the
significance that SMARCB1 loss plays in initiation and disease progression of
RMC will provide opportunities for therapeutic intervention for RMC. In addition, a
better understanding of how high-intensity exercise and the consequential hypoxia
leads to RMC can also help shape clinical recommendations for individuals with
SCT who are interested in participating in activities that may involve high-intensity
exercise, such as professional sports or military service. Our work has already
demonstrated that the connection between SCT and SMARCB1 loss seen in RMC
patients is likely the ischemia/hypoxia caused by sickling RBCs in the inner renal
medulla. We have also shown how high-intensity exercise can exacerbate renal
hypoxia in the presence of SCT. However, we have yet to prove whether hypoxia
is the driver of tumor initiation and progression in RMC.

As we discussed previously, a major limitation in our study is the lack of tumor
development in our SCT mouse models. Given the fact that RMC is relatively rare,
we would need an exceptionally large cohort of mice. To overcome this limitation,
future experiments would include exposing mice to hypoxic conditions or highintensity exercise following SMARCB1 ablation in order to add a selective pressure
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to accelerate tumorigenesis. If hypoxia is truly a driver of tumor initiation and
progression, it is expected that these events will accelerate the onset of
tumorigenesis and exaggerate tumor progression. Renal cell carcinoma (RCC),
which is driven by Von Hippel-Lindau (VHL) mutation causing a hypoxia signature,
alludes to the fact that RMC, and possibly other hypoxic tumors like pancreatic
cancer, might require hypoxic signaling to drive tumorigenesis and disease
progression.

In addition, the results of this study could provide novel insight into the role of the
SWI/SNF complex in hypoxia and pathophysiology. To further investigate the
mechanisms driving the degradation of Smarcb1 in hypoxia, we plan to perform
proteomic analysis using mass spectrometry to identify post-translational
modifications to support our findings with SDM, and also binding partners, such as
E3 ubiquitin ligases. The identifications of such partners and modifications can
lead to deeper molecular understanding and possibly new therapeutic targets for
treating RMC and other SMARCB1-deficient malignancies. We have shown that
SMARCB1 loss is potentially protective to cells in hypoxia. Although, this finding
does not directly relate to the treatment of RMC, it may help us better understand
other diseases with SMARCB1-deficiency or SMARCB1 hotspot mutations.
Therefore, diseases that are characterized by SMARCB1 hotspot mutations, such
as Coffin-Siris syndrome and other developmental diseases may actually be
diseases that impair the functional role of SMARCB1 in cellular hypoxia response.
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Interestingly, we also showed that SMARCB1 positive cells were more susceptible
to hypoxia in high glucose media compared to SMARCB1-deficient cells (Figure
32), suggesting that the survival fitness conferred by SMARCB1 loss is related to
metabolic mechanisms. This data supports an emerging body of data that
suggests that diseases with SWI/SNF mutations are metabolic diseases. Although,
the relationship between SMARCB1 and hypoxia is largely unknown, the role of
the

SWI/SNF

complex

in

metabolism has

been

well-characterized

in

Saccharomyces cerevisiae (S. cerevisiae), also known as Baker’s yeast. Early
studies in S. cerevisiae have demonstrated that the SWI/SNF complex plays a
critical role in regulating carbohydrate metabolism, eluding to its potential
importance in human metabolism.

In fact, genes encoding the different subunits of the SWI/SNF complex were first
identified using genetic screens in S. cerevisiae (111). These genetic screens
demonstrated that SMARCB1 (known as SNF5 in S. cerevisiae) was required for
high levels of SUC2 gene expression in S. cerevisiae. In S. cerevisiae, the SUC2
gene encodes for invertase, an enzyme that catalyzes the hydrolysis of sucrose
into glucose. Therefore, Carlson et al. concluded that SNF5 was a positive
regulator of genes that activate (derepress) SUC2 in order to increase glucose
levels in S. cerevisiae under a nutrient deprivation state (111). The role of
SMARCB1 as a modulator of glucose regulating genes in S. cerevisiae suggests
that SMARCB1 could potentially play a key role in metabolic reprogramming in
cells as a response to environmental stress.
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These findings in S. cerevisiae lead us to hypothesize that the initial fitness
conferred by the loss of SMARCB1 seen in RMC might be a metabolic advantage
in harsh conditions such as hypoxia and nutrient deprivation. Our studies show
that the loss of SMARCB1 does not lead to a significant increase in cell
proliferation. In addition, re-constitution of SMARCB1 does not reduce the growth
of renal tumor cells (Figure 31, Figure 33). Elucidating the role of SMARCB1 and
the SWI/SNF complex as a whole in metabolic regulation in disease progression
will provide molecular targets, such as critical metabolites needed for tumor cell
survival and progression, that can be leveraged therapeutically to treat RMC and
other malignancies that are characterized by SWI/SNF complex mutations. As
mentioned earlier, there is emerging data suggesting that diseases such as cancer
that are characterized by SWI/SNF complex mutations are metabolic diseases.
The potentially unique metabolic features associated with SWI/SNF complex
mutations can provide opportunities for targeted therapeutic intervention. Overall,
there is still work needed to solidify our findings with deeper biochemical studies.
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